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ABSTRACT

Human adenovirus type 4 (HAdV-E4) is a causative agent of acute
respiratory disease and conjunctivitis worldwide. Two major lineages of HAdV-E4
genomic variants have been identified by their distinct BamHI restriction profiles:
prototype-like (p-like) strains and the a-like genomic variants. Recent molecular
epidemiology studies have shown a predominance of a-like genomic variants
detected in association with disease which suggests a-like strains have a fitness
advantage or they may be more pathogenic. The impact of HAdV-E4 intratypic
genetic variability on in vitro and in vivo phenotypes relevant to pathogenesis is a
major gap in knowledge. I hypothesize that HAdV-E4 comprises two distinct
evolutionary lineages that differ in their in vitro growth and in vivo pathogenetic
phenotypes. Whole genome sequences (WGS) from 45 HAdV-E4 strains isolated
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between 1953 and 2015 clustered into two phylogroups: phylogroup I (PG I)
includes the p-like strains and phylogroup II (PG II) comprises the a-like variants.
Bioinformatics analysis of WGS identified divergence at multiple genomic loci
that may contribute to differences in in vitro and in vivo pathogenic phenotypes.
In cell culture, PG I strains formed larger plaques, exhibited an enhanced cell
killing phenotype, and replicated faster compared to PG II strains. Interestingly,
infection with a PG II strain resulted in more severe pulmonary pathology in a
cotton rat model of HAdV respiratory infection. The results of this study set the
foundation for future efforts to elucidate the molecular basis of HAdV-E4
pathogenesis by comparing these in vitro and in vivo phenotypes using isogenic
mutant viruses.
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Chapter 1 – Introduction
1.1 Adenoviruses
Adenoviruses (AdVs) are nonenveloped double-stranded DNA viruses that
infect vertebrates. AdVs were first isolated independently by two groups in 1953
and 1954: Rowe and colleagues isolated AdV while attempting to culture
adenoids and Hilleman and Werner isolated AdV from a throat washing from a
military recruit presenting with acute respiratory disease (ARD) (1, 2).
Human adenovirus (HAdV) infections are associated with a wide variety of
diseases among immunocompetent individuals including respiratory disease,
ocular disease, and gastrointestinal disease (3). Among immunocompromised
individuals, infections can result in renal, myocardial, hepatic, and disseminated
disease (3). The more than 60 years of AdV research have contributed to
numerous fundamental discoveries of basic biology, including the discovery of
mRNA splicing (4, 5). The extensive knowledge of the biology of AdVs has also
aided in the development of AdVs as gene delivery tools, platforms for numerous
vaccines (including the ChAd3-EBO-Z vaccine against Ebola (6–8), currently in
phase I clinical trials in the United States
(https://clinicaltrials.gov/ct2/show/NCT03583606?term=chad3-ebo-z&rank=2)),
as well as oncolytic agents (9).

1.2 Taxonomy
Adenoviruses belong to Family Adenoviridae which currently comprises
five genera accepted by the International Committee on Taxonomy of Viruses
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(ICTV): Atadenovirus, Aviadenovirus, Ichtadenovirus, Mastadenovirus, and
Siadenovirus. AdVs isolated from mammals belong to the genus Mastadenovirus
or Atadenovirus. AdVs that infect birds are classified within the genus
Atadenovirus, Aviadenovirus, or Siadenovirus. AdVs that infect reptiles are
classified in the genus Atadenovirus or Siadenovirus. Finally, only one AdV has
been isolated from a fish and is classified in the genus Ichtadenovirus (10, 11).
The ICTV recognizes 45 species classified within genus Mastadenovirus.
The known human AdVs (HAdVs) are classified into seven species, designated
Human mastadenovirus A to G (HAdV-A to HAdV-G) (10, 12). While the ICTV is
charged with the responsibility of classifying viruses on the species level, further
classification including naming and assigning strains to an existing species is
accomplished by the research community by peer review
(https://talk.ictvonline.org/taxonomy/w/ictv-taxonomy) (13). Originally, 51
serotypes were identified based on serological criteria including virus
neutralization (VN) against reference hyperimmune animal sera and
hemagglutination inhibition (HI) assays (14–17). Molecular typing using
restriction fragment length polymorphism (RFLP) analysis facilitated the rapid
identification and characterization of intratypic genetic variability. While this
method continues to be used today, the advent of whole genome sequencing has
allowed greater resolution of genomic data at a relatively inexpensive cost.
Whole genome sequencing is used to identify differences in intratypic variants,
and is now commonly used to identify and characterize new genotypes (18).
Genotyping has replaced serotyping in the identification of novel AdVs as VN and
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HI have become increasingly uncommon. Whole genome sequencing provides
an affordable and reliable method to accurately characterize novel AdVs. Criteria
for describing a novel HAdV genotype include phylogenetic analysis of the
genome sequence with particular emphasis on the identity of the penton base,
hexon, and fiber genes. Recombinant AdVs are also classified as new genotypes
as long as sufficient genomic, biological, or pathological differences are
demonstrated when compared to related genotypes (18, 19). The HAdV Working
Group was formed to establish the criteria for the characterization and naming of
novel HAdVs. In addition, they also help coordinate naming of new genotypes to
reduce confusion in the literature. This group works with the National Center for
Biotechnology Information and is composed of a committee of researchers with
expertise in AdV typing (18). Under the new typing system, 35 additional
genotypes (HAdV-D53 to HAdV-D90) were described and recognized by the
HAdV research community between 2007 and 2018. The reported genotypes are
listed in Table 1 (20). The genotype designations include “HAdV-“ followed by the
letter referring to the species and their genotype number. As an example,
genotype 1 from species Human mastadenovirus C is designated as “HAdV-C1”.
To avoid confusion, each genotype is assigned a unique sequential number, so
there will be not be “HAdV-C1” and an “HAdV-D1”. The complete genome
sequences of all types, including the original 51 serotypes are publicly available
for reference in the GenBank database (12). Despite the establishment of the
HAdV Working Group (18), debate regarding the criteria used to designate new
types continues (21, 22).
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Table 1: Taxonomy and Tropism of HAdVs

1.3 Structure
HAdVs are nonenveloped viruses with an icosahedral capsid symmetry.
The capsid is formed from 240 hexon capsomers and 12 penton capsomers with
a pseudo T = 25 triangulation number (23, 24). A trimeric fiber protrusion is
associated with each penton base with an approximate length of 300 Å (25).
Most AdVs encode a single fiber with the notable exceptions of members of
HAdV-F, HAdV-G, as well as some simian, fowl, and lizard AdVs which encode
two fibers (26–32). The capsid is also composed of four minor capsid proteins:
IIIa, VI, VIII, and IX. Proteins V, VII, IVa2, μ, terminal protein (TP), and protease
are packaged with the viral genome (23, 25). The virions have an average
diameter of 950Å (25).
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1.4 Genome Organization of Adenoviruses
AdVs have a linear double-stranded DNA genome that varies in size
depending on the species (11). The HAdV genome is approximately 34 kb to 36
kb in length (11). The genome organization varies significantly among the
different AdV genera, especially in genes thought to be genus-specific, namely
those in early region 1 (E1), early region 3 (E3), and early region 4 (E4) (11). A
genome organizational map for HAdV is shown in Figure 1. All AdVs have
inverted terminal repeats (ITRs) on the extreme termini of the genome which are
important for DNA duplication (11). The expression of genes encoded in the AdV
genome is temporarily regulated in three major phases: early, intermediate, and
late. The general functions of HAdV-encoded genes are listed in Table 2.

Figure 1: Genome organization of HAdV-E4
The 36 kb double stranded genome of HAdV-E4 encodes 13 temporally
regulated transcriptional units: early (blue), intermediate (purple), and late (red).
L1-L5 comprise the major late transcriptional unit. Forward and reverse arrows
indicate transcriptional units encoded on the right (R) or left (L) strands,
respectively. The locations and sizes of the CDS for each transcriptional unit are
approximate. The noncoding virus-associated (VA) RNAs are shown in green.
Adapted from Akusjarvi G, 2008 (33).
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Table 2: AdV Gene Products and Functions

1.5 The Adenovirus Life Cycle
The adenovirus life cycle has been most extensively studied for members
of HAdV-C. The life cycle is divided roughly into two phases: early and late. The
early phase comprises events that prepare the cellular environment for viral DNA
replication following entry of the virus into the cell. The late phase includes viral
DNA duplication, expression of structural proteins, assembly of virions, and viral
progeny egress from the infected cell. Some HAdV protein products are also
produced at intermediate times as noted in Table 2. Figure 2 represents the
highlights of the adenovirus replication cycle, which is summarized in sections
1.5.1 and 1.5.2.
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Figure 2: Summary of the adenovirus Life Cycle
The adenovirus life cycle is divided into two major phases: early and late. Viral
attachment is mediated by a cellular host receptor (1) followed by clathrinmediated endocytosis. (2). The viral particle undergoes partial disassembly
before escaping into the cytosol (3) where it traffics to the nuclear pore complex
via the microtubule network (4). The viral genome is released into the nucleus
and transcription of the E1 genes commences (5). E1 transcripts are translated
(6) and transported into the nucleus where they act as transactivators to assist
in driving the expression of other early genes (7). Early gene products have
many functions including modulating apoptosis and the host response to
infection. Some early gene proteins are transported into the nucleus where they
assist in replication of the viral genome using a strand displacement mechanism
(9). During viral DNA replication, the major late promoter is activated which
drives the expression of all late genes (10). The virus shuts down host cell
translation at late times post infection (11). The majority of the late viral
transcripts encode structural proteins which are shuttled into the nucleus where
viral assembly occurs (12). Progeny virions escape the cell using a lytic
mechanism.

1.5.1 Early phase
Viral attachment and entry into the cell is mediated by several different
HAdV species-specific surface receptors. The coxsackie and adenovirus receptor
(CAR) is used by species A, C, D, E, and F, while CD46 and desmoglein-2 are
7

used by species B. Studies have demonstrated that some members of HAdV-D
have a low affinity for CAR and instead may use sialic acid. Scavenger receptors
on Kupffer cells have also been shown to mediate HAdV attachment (34).
Interaction between the RGD motif of the HAdV penton base and cellular
integrins, including α3β1, α5β1, αvβ1, and αvβ1, facilitates receptor-mediated
endocytosis in clathrin-coated vesicles (35, 36), and pH changes in the early
endosome facilitates partial disassembly of the virion. Protein VI aids in rupture
of the endosome and subsequent release of the virion in to the cytoplasm (37).
The virion is then transported to the nucleus via dynein motor proteins on the
microtubules (38). The viral DNA is then imported into the nucleus (39).
The E1A transcription unit encodes two major proteins which are the first
viral protein products detected in infected cells. E1A proteins have two major
functions: to stimulate the host cell into S phase (40), and to stimulate the
expression of other HAdV early genes (41, 42). E1A transcripts are alternatively
spliced into two major mRNAs that give rise to the large and small E1A proteins
(43). The large E1A protein has four distinct regions of conservation (CR1
through CR4) shared among all HAdV species (44). The small E1A protein only
includes CR1, CR2, and CR4 (see Figure 3). Both the large and small E1A
proteins are sufficient to push the cell into S phase through interactions between
the CR1 and CR2 regions and the retinoblastoma protein (RB), the p300/CREBbinding protein (CBP) complex, and the RB-like proteins p107 and p130 (45, 46).
Stimulation of S phase (particularly the inactivation of RB through interaction with
E1A) induces apoptosis (47).
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Figure 3: E1A conserved regions and protein-protein interactions
The E1A transcript is alternatively spiced into two major protein products: large
and small E1A proteins (above and below, respectively). E1A proteins have four
conserved regions (CR1 through CR4) that interact with a number of cellular
proteins to both push the cell into S phase and active viral early gene
transcription. The major interacting proteins are listed.

The E1B transcriptional unit encodes two polypeptides, E1B 19K and E1B
55K, which are translated from two different initiation codons in different reading
frames (48). Both proteins serve important functions in blocking p53-dependent
induction of apoptosis through different mechanisms. E1B 19K, a BCL2 homolog,
stabilizes the proapoptotic cellular proteins BAK and BAX. During apoptosis, BAK
and BAX form high molecular weight pore complexes imbedded in the
mitochondrial membrane and allow the release of cytochrome C and
SMAC/DIABLO (49). E1B 19K prevents the oligomerization of BAK and BAX,
thus preventing apoptosis (50). On the other hand, E1B 55K stabilizes p53 and
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the E1B 55K/E4 ORF6 complex recruits cellular E3 ubiquitin ligase components
and selectively degrades p53, Mre11, DNA ligase IV, and other cellular
components (45, 51–53). The E1B proteins also perform other functions such as
suppressing the interferon (IFN) response and transporting viral mRNAs to the
cytoplasm at late times during infection (54, 55).
The larger E1A protein stimulates expression of the other early viral genes
between 10 and 100 fold though interaction with MED23 and other cellular
transcription factors, which confers tight control of viral gene expression (46, 56,
57). The early region 2 (E2) gene products encode the viral DNA-dependent
DNA polymerase (pol), preterminal protein (pTP, which is later proteolytically
cleaved to TP), and the DNA binding protein (DBP), all necessary for viral DNA
replication. The E4 transcriptional unit encodes several alternatively spliced
mRNAs that code for 6 unique proteins which have a variety of functions
including inhibition of the IFN and double stranded break repair responses (58).
The E3 transcriptional unit encodes species-specific repertoires of open
reading frames (ORFs) encoding between five and nine proteins (59), and is
dispensable for viral replication in vitro (60). The organization of E3 for the
different HAdV species is shown in Figure 4. The species B,C,D, and E-specific
E3 gp/19K protein interacts with the MHC class I molecules in the endoplasmic
reticulum (ER) and prevents their translocation to the cell surface, interfering with
antigen presentation (61). This function greatly reduces the pulmonary
inflammatory response to HAdV infection in cotton rats (62). The membrane
proteins RIDα and RIDβ are conserved among the HAdV species and work
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together to downregulate cell surface expression of CD95 (Fas receptor) (63–
65). The cytosolic 14.7K protein, which is also conserved among all HAdV
members, functions to protect cells from TNF-mediated lysis (66, 67). Each
HAdV species encodes two to four E3 CR1 ORFs (CDD: pfam02440) which
encode nonstructural membrane glycoproteins of variable size. These proteins
share some homology with the RL11 family of proteins encoded by human
cytomegalovirus (68). The most extensively studied E3 CR1 protein, HAdV-C
adenovirus death protein (ADP), is expressed at late time points post infection
and facilitates efficient viral progeny release (69). In contrast, the E3 CR1 ORF
located in the same region as ADP in the genomes of members of HAdV-D
encodes a 49 kDa protein which is secreted and interacts with CD45 on
lymphocytes and modulates their function (70). Martinez-Martin and colleagues
recently used an extracellular protein microarray to screen for cellular proteinprotein interactions with the ectodomain of HAdV E3 CR1 proteins from all
species. Several candidate interactors were described (71), and future work is
needed to validate these interactions during infection.
The ~150-200 nucleotide noncoding virus-associated RNA (VA RNA)
transcripts VA RNAI and VA RNAII start to accumulate at early times post
infection (72) and form highly structured RNAs (73). RNA polymerase III (Pol III)
transcribes these RNAs under the control of a highly conserved internal Pol III
promoter consisting of the promoter elements A and B (74). These transcripts
function to suppress protein kinase R (PKR) activation by acting as competitive
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substrates. In addition, they suppress RNAi by saturating the DICER complex
(75).

Figure 4: Organization of E3 among the different HAdV species
E3 Open reading frames (ORFs) are represented by boxes and aligned based
on homology and location in the genome. Space between ORFs is not indicative
of the untranslated region between ORFs. The ORFs for HAdV-E4 are based on
the CL68578 sequence (AY487947). Adapted from Burgert and Blusch (59).

1.5.2 Late phase
The late phase of infection in hallmarked by DNA duplication and high
activity levels of the major late promoter (MLP), which drives expression of the
late genes. Viral DNA replication is facilitated by three viral proteins: pol, TP and
DBP. Several cellular proteins also aid in DNA replication including NFI, NFIII,
and OCT1. TP is covalently attached to the 5’ end of AdV DNA. AdV pol initiates
at the 5’ end, using TP as a primer, and uses a strand displacement mechanism
for duplication. The NFI and NFIII DNA binding motifs in the left hand inverted
ITR also greatly enhance initiation for HAdV-C2 and HAdV-C5 (76). Interestingly,
12

the HAdV type 4 (HAdV-E4) prototype strain RI-67 only carries the NFIII
recognition site, and both NFI and NFIII are dispensable for initiation of
replication (77, 78). The freed single-stranded DNA molecule then circularizes to
form a panhandle using the complementary sequences at the 5’ and 3’ ITR. This
structure is recognized by pol, and synthesis is initiated again using strand
displacement, with the result of two linear double-stranded DNA molecules (79).
Viral and cellular RNAs are translated simultaneously during the early
phase of infection. In the late phase, however, viral transcripts are translated
nearly to the exclusion of all cellular transcripts. This is accomplished by first
shutting down host cell translation by dephosphorylation of eIF4E, an important
eukaryotic initiation factor that binds to the 5’ 7-methyl guanosine cap structure.
Phosphorylation is normally accomplished by the cellular Mnk1 kinase which is
bound to eIF4G. Mnk1 is displaced by the viral L4-100K protein, and host cell
translation stops due to the dephosphorylated state of eIF4E (80, 81). An
alternative form of translation is then used to synthesize late viral proteins:
ribosome shunting. The 200 nucleotide non-coding tripartite leader (TPL)
sequence spliced onto the 5’ end of all late viral mRNAs eliminates the need of
scanning by the 40s ribosome subunit for the initiator start codon, instead, the
ribosome is shunted directly to the initiator start codon directly after the TPL
sequence (82, 83).
Progeny virions are assembled in the nucleus. The multifunctional L4100K protein facilitates folding and trimerization of the hexon subunits and
subsequent transport into the nucleus (84). Assembly of pentameric penton

13

structures and association with trimeric fiber units is accomplished in the
cytoplasm and subsequently imported into the nucleus (85, 86). Viral DNA is
packaged into capsids, and minor structural proteins are proteolytically
processed by the viral protease and incorporated into the virion (24, 25).
Viral progeny release is thought to occur through a lytic mechanism. For
the six HAdV-C genotypes, the species-specific E3 protein ADP has been shown
to be necessary for efficient release of mature viral particles (69, 87). Mutants
lacking ADP produced similar titers of total infectious virus in submerged
monolayer cultures in vitro. However, titers from cell culture supernatant were
lower compared to those of WT-infected cells. Increased lysis of infected cells,
dissemination in monolayers, and large plaque sizes are hallmarks of HAdV-C
genotypes encoding ADP (69). The mechanism by which ADP functions is still
under investigation. However, a yeast two-hybrid screen revealed interactions
with MAD2 (88). Aberrant control of apoptosis due to mutations in the E1B 19K
coding sequence or low levels of E1B 19K expression can also result in a large
plaque phenotype (89, 90). Another mechanism of viral progeny release is
thought to be cleavage of cytokeratin 18 by the late region 3 (L3) 23K protease,
which has an overall effect of weakening the cytokeratin system and promoting
cell lysis (91). Disruption of tight junctions by the PDZ protein-binding complex of
E4 ORF1 or free fiber interactions with the tight junction protein CAR might also
facilitate viral progeny release in HAdV-C (92, 93).

14

1.6 Diseases Associated with Human Adenovirus Infection
HAdVs are ubiquitous pathogens that are associated with a wide variety of
diseases (3, 94). Causative agents of respiratory disease of variable severity
include members of species HAdV-B, HAdV-C, and HAdV-E. Infections with
HAdV-B, HAdV-D and HAdV-E strains have been associated with ocular disease,
such as conjunctivitis. The more severe keratoconjunctivitis is specifically
associated with infections by HAdV-D types 8, 19, and 37 (94, 95), and to a
lesser extent by HAdV-E4 (96, 97). Infection of the gastrointestinal (GI) tract has
been noted for members of HAdV-A, HAdV-D, HAdV-F, and HAdV-G (3, 94).
Immunocompromised individuals, such as transplant recipients, patients
receiving chemotherapy, or HIV-positive patients, are more susceptible to HAdV
infections (98). Additionally, persistence in the GI tract has been described for
most species (99, 100).
Adenovirus tropism is dependent on structural proteins, most importantly,
the fiber protein (34, 36). As shown above, viruses from different species can
have similar tropisms, even while using different receptors for attachment and
entry. Retargeting AdV viral vectors by manipulating the hexon, penton, fiber,
and pIX proteins can successfully alter tropism (101).

1.7 Animal Models of Acute Viral Pathogenesis
There are no suitable animal models of HAdV respiratory infection that
recapitulate the full spectrum of virus-host interactions underlying human
disease. Early attempts to develop an animal model began shortly after the initial
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discovery of HAdV, although the animals tested, including mice, guinea pigs,
hamsters, rabbits, and rhesus macaques, did not develop clinical symptoms (1).
Currently, the most widely used small animal models are the mouse (Mus
musculus), the Syrian hamster (Mesocrietus auratus), and the cotton rat
(Sigmodon hispidus). HAdVs do not replicate in the lungs of intranasally-infected
mice, although pneumonia, similar to that seen in humans, is observed (102).
Despite these limitations, this model has been extensively used to study the role
of early AdV genes in pathogenesis (103). A humanized mouse model has also
been developed that recapitulates some features of acute and persistent
infections (104).
The Syrian hamster model is almost exclusively used to study oncolytic
viruses (105). A recent study observed positive immunohistochemical staining for
virus structural proteins in bronchial epithelial cells of immunosuppressed
hamsters inoculated intranasally with HAdV-C5 and HAdV-C6. While a higher
burden of HAdV-C6 was observed in the lungs of infected animals, the authors
did not demonstrate viral replication over time (106). This model has also been
used to study the effects of antiviral drugs in respiratory infections (107, 108).
The cotton rat model is semipermissive to HAdV infection with modest
viral replication in the lungs (109, 110). Similar to mice, cotton rats develop
pneumonia upon infection with HAdV-C (110). This model has been used to
study the role of early genes in adenovirus pathogenesis as well (111, 112). The
importance of the proteins encoded in E3 was discovered using the cotton rat
model. Ginsberg and colleagues observed significantly enhanced pulmonary
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pathology in animals infected with a gp/19K knock out (KO) HAdV mutant,
showing the importance of this protein in modulating the host response to
infection (62). The majority of the studies to date examined pulmonary pathology
that resulted from internasal infection with HAdV-C strains. Pacini and colleagues
reported recovering the highest viral titers from adult animals infected with HAdVC types (-C1,-C2,-C5, and HAdV-C6) while recovering very little or no virus from
infection with HAdV-B3, HAdV-E4, and HAdV-B7 (109). Further refinement of this
model is needed in order to investigate if this model can support infection with
other genotypes.

1.8 Human Adenovirus Type 4
HAdV-E4 is unique in that it is the only human member of species Human
mastadenovirus E (HAdV-E). HAdV-E also includes 12 simian AdVs (SAdV)
types based on phylogenetic analysis: SAdV22, SAdV23, SAdV24, SAdV25,
SAdV25.2, SAdV 26, SAdV30, SAdV36, SAdV37, SAdV38, SAdV39, and
CHAdV-Y25 (113, 114).
It has been proposed that HAdV-E4 is the result of a zoonotic homologous
recombination event between a yet unidentified SAdV and HAdV-B16.
Bioinformatics analysis revealed HAdV-E4 consists of a “genome chassis” of
SAdV26-like genome and loops 1 and 2 of the HAdV-B16 hexon (115). Unlike
other HAdV species (12, 116, 117), HAdV-E does not undergo intraspecies
homologous recombination as a source for genetic diversity as HAdV-E4 is the
only human type in this species.
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HAdV-E4 was originally isolated from a throat washing from a military
recruit presenting with primary atypical pneumonia at Fort Leonard Wood,
Missouri during the winter of 1952-1953 (2). Additional reports detail the leading
role of HAdV-E4 as a causative agent of ARD in the military recruit training
environment (118). In civilian populations, HAdV-E4 infections are continually
associated with ARD (119, 120) as well as pharyngoconjunctival fever (121–
123), conjunctivitis (124–127), and pneumonia (128).
HAdV-associated ARD constituted a significant burden among recruits at
military training facilities in the United States in the 1950s and 1960s (129, 130).
This prompted the development of the enteric coated bivalent live HAdV-E4 and
HAdV-B7 vaccine for use only in military recruits (131, 132). The vaccine was
tested extensively and shown to reduce ARD associated with HAdV infections
(133, 134). Furthermore, a cost-benefit analysis demonstrated the value of
vaccination (135). Vaccination protocols were implemented in all military recruits
starting in 1971. By 1997, production problems resulted in the discontinuation of
vaccination protocols (136). During the lapse in vaccination, continuous
outbreaks of HAdV-associated ARD were reported in recruit training centers
across the United States (137–141). A new manufacturer commenced production
of the vaccine and restoration of vaccination protocols restarted in 2011 resulting
in a dramatic reduction in the number of HAdV-associated ARD cases (142,
143).
HAdV-E4 has also shown some promise as a platform for other vaccines.
Researchers have developed influenza vaccines based on the HAdV-E4 or
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HAdV-B7 backbone with the rationale of vaccinating against both HAdV-E4 or
HAdV-B7 and influenza through the enteric route (144, 145).

1.9 Human Adenovirus Type 4 Genetic Variability
RFLP (also referred in the literature as restriction enzyme analysis) has
been used since the 1970s to distinguish HAdVs based on their genetic
variability (146, 147). Importantly, this technique was able to discriminate
genomic variants of a single genotype that were serologically indistinguishable
before the widespread use of DNA sequencing (148–150). Two distinct
evolutionary lineages of HAdV-E4 genomic variants have been described to the
present: one comprising the p-like strains and another comprising the a-like
genomic variants (149). Following the isolation of the prototype strain RI-67 (4p)
in 1953 (2), other closely related strains (demonstrated by VN and RFLP
analysis) were isolated from military recruits (147, 149). Of note, the vaccine
strain, CL68578, was isolated in 1963 (131) and has been given the genomic
variant designation “4p1”, although this is erroneous as benchtop and in silico
RFLP analysis shows 4p and 4p1 strains have identical profiles (including the
SmaI endonuclease profile, which was the only enzyme thought to produce a
distinct profile) (151). The 4p4 genome variant, distinguishable by RFLP analysis
using the EcoRI enzyme, was the only p-like strain isolated among unvaccinated
recruits between 1997 and 2006 (139). A recent study sequenced a p-like strain
from a civilian isolated in 1986 and was found to be of the 4p4 variant (152). The
a-like genomic variants are profoundly distinguishable from p-like genomic
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variants by RFLP analysis, only sharing ~45-60% percent comigrating restriction
fragments (PCRF) (147, 149, 153). Multiple 4a genomic variants have been
identified (128, 139, 149). The earliest reported a-like strain was a Chinese
isolate from 1965, although information on the isolate is limited (149, 154). After
1965, a-like genomic variants were isolated from patients presenting with both
respiratory and ocular disease worldwide (125, 126, 147). Molecular
epidemiology studies of HAdV-E4-associated ARD in United States military
recruits revealed frequent isolation of a-like genomic variants (139). Furthermore,
a predominance of a-like genomic variants were isolated from patients presenting
with influenza-like illness in the northeastern United States between 2011 and
2015 (128).
Limited comparative bioinformatics analysis is available for the two
lineages of HAdV-E4 genomic variants. Dehghan and colleagues reported two alike genomic variant WGS to have 95.1% sequence identity to RI-67 strain (115).
Divergent regions between the two evolutionary lineages of HAdV-E4 variants
map to the ITRs, VA RNAII, as well as the E1 and E3 regions (115, 155, 156).
Both p- and a-like genomic variants are remarkably similar to SAdVs
classified within HAdV-E. This observation was originally made by comparison of
comigrating fragments using RFLP analysis (147, 149), and later by comparison
of whole genome sequences (114, 115, 157). a-like genomic variants were
shown to have ~89-90% sequence identity to SAdVs (115) and the p-like strain
RI-67 has 91.5% sequence identity to SAdV26.
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1.10 Molecular Epidemiology of Human Adenovirus Type 4 Infections
The identification of HAdV-E4 as a causative agent of outbreaks of ARD in
military recruits prompted researchers to investigate the epidemiology HAdV-E4
infections in this specific population. Outbreaks were seasonal, with high rates of
infection occurring during the cold winter months (peaking in February) and low
infection rates in the warm months (129, 158). In a study conducted at Fort Dix, it
was found that 80% of military recruits were infected with HAdV-E4 during their
basic training. Furthermore, 25% of the infected recruits would develop minor
symptoms, and an additional 25% would require hospitalization (129). Many
conditions are thought to contribute to the spread of HAdVs in these populations:
overcrowding in military barracks, high levels of stress, and the ability of HAdVs
to remain viable on surfaces and fomites for long periods of time (159, 160).
Implementation of the HAdV-E4 vaccine (in combination with the HAdV-B7
vaccine) in 1971 greatly reduced the burden of HAdV-associated ARD in military
training facilities (161).
As discussed previously, a discontinuation of HAdV-E4/B7 vaccination
protocols occurred in the United States military between 1997 and 2011. During
this lapse in vaccination, reemergence of vaccine-preventable ARD was
observed (137–139, 141, 162). A dramatic decline in HAdV-E4-associated ARD
cases was observed upon reimplementation of vaccination protocols in 2011
(142, 143). In addition, Broderick and colleagues also found that environmental
samples collected at barracks and medical clinics at training facilities after 2011
were routinely negative, compared to 27% of environmental samples testing
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positive for HAdV by polymerase chain reaction (PCR) before the 2011
reimplementation of the vaccine (143).
HAdV-E4 outbreaks in civilian populations have also been reported
worldwide, although surveillance programs specifically targeting HAdV infections
are limited (163, 164). Molecular epidemiology data from recent studies suggest
a predominance of a-like strains over p-like strains are currently circulating in
association with disease. This was recently highlighted by Kajon and colleagues
in a survey of cases of HAdV-E4 respiratory infections in the Northeast United
states (128). In this study, only one of the examined strains belonged to the p-like
lineage (genetically different from the vaccine strain), while all others were a-like.
In a molecular epidemiology study examining 1500 HAdV-E4 isolates from
military recruits during the lapse in vaccination (Figure 5), 90% of the isolated
strains were found to be a-like (139). The factors that contribute to a-like strains
being isolated more frequently than p-like strains in association with disease is
unknown.
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Figure 5: Molecular epidemiology of HAdV-E4 respiratory infection among
military recruits presenting with ARD
Each row represents a single military recruit training facility (CA, Marine Corps
Recruit Depot, San Diego, California; TX, Lackland Air Force Base, San Antonio,
Texas; MO, Fort Leonard Wood, Missouri; IL, Naval Recruit Training Command,
Great Lakes, Illinois; GA, Fort Benning, Georgia; SC, Fort Jackson, South
Carolina; SC, Marine Corps Recruit Depot, Parris Island, South Carolina; NJ,
Coast Guard Training Center, Cape May, New Jersey). Each box represents a
single isolate genotyped by RFLP analysis.

1.11 Gaps in the Knowledge
HAdV-E4 intratypic genetic variability has been described since the 1980s
(146, 147, 149). RFLP analysis with up to 16 endonucleases was used to
distinguish p-like and a-like genomic variants. The description of genetic
variability using this approach was low resolution as only ~2% of the 36 kb
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genome was analyzed (149), although still valuable for analyzing large numbers
of samples in epidemiology studies (21). The advent of next generation
sequencing (NGS) and the decline in its cost in recent years have provided an
affordable platform for examining differences among WGS, nucleotide by
nucleotide. Dehghan and colleagues compared WGS from two a-like strains to
the prototype and vaccine p-like strains (115). In this study the authors only
discussed differences in the hexon and ITR sequences. A more detailed
description of other regions of the genome is needed as it is likely that there are
other important sequence differences in other regions of the genome. Larger
collections representing the identified spectrum of genetic variability also need to
be examined.
The observation of the relative predominance of a-like strains over p-like
strains among circulating HAdV-E4 strains suggests that a-like strains may have
a fitness advantage, such as transmissibility, or an enhanced ability to replicate
in the host. Furthermore, it is also possible that a-like strains are more
pathogenic as most studies only characterize virus isolates from cases of
disease and not from asymptomatic individuals. The factors that contribute to the
detection of a-like strains more frequently in association with disease remains is
a gap in the knowledge.
Descriptions of replication kinetics and biological features of HAdV-E4
were published within 15 years of the discovery of AdV by Maurice Green, Harold
Ginsberg, and others (165–168). Basic biological descriptions of p-like and a-like
strains, however, have not been reported with one important exception:
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Crawford-Miksza and colleagues described sequence differences in the
hypervariable regions (HVR) 1-7 HVRs of the hexon sequences between the RI67 strain and an a-like strain designated ZG 95-873 that were associated with a
fourfold difference in the neutralization titers (169). The results from this study
provide the rationale to examine other regions of the genome to identify genetic
differences that may confer differences in phenotypes relevant to pathogenesis.
The implications of HAdV-E4 intratypic genetic variability in pathogenesis
are not known. The hypothesis that HAdV intratypic genetic variability contributes
to discriminable in vitro and in vivo phenotypes has only been explored to a
limited extent in the AdV literature. As an example, Radke and colleagues
reported the HAdV-B14p1 genomic variant exhibited low levels of E1B 19K
expression which resulted in larger plaque sizes and enhanced
immunopathogenesis in the Syrian hamster model compared to the HAdV-B14
prototype virus (90), despite that these two viruses are ~99.7% identical (170).
Dehghan and colleagues reported ~95% sequence identity between the HAdVE4 a-like strains and the prototype strain with important differences mapping to
the ITRs (115); however it is not clear if these or other genetic differences
contribute to variability in phenotypes that are relevant to pathogenesis. This
remains a significant gap in the current knowledge.

1.12 Hypothesis and Specific Aims
I hypothesize that HAdV-E4 comprises two distinct evolutionary lineages
that differ in their in vitro growth and in vivo pathogenetic phenotypes.
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In this dissertation, this hypothesis was tested through the execution of the
following specific aims:

Specific Aim 1 – To characterize the HAdV-E4 genetic variability by examination
of WGS of a large collection of strains isolated worldwide between 1953 and
2015.

Specific Aim 2 – To evaluate the contribution of HAdV-E4 intratypic genetic
variability to in vitro and in vivo phenotypes relevant to pathogenesis.
Subaim 1 – To compare the growth and cell killing phenotypes of HAdVE4 PG I and PG II genomic variants in cell culture
Subaim 2 – To compare the pulmonary pathogenic phenotypes of HAdVE4 PG I and PG II genomic variants in a cotton rat model of HAdV respiratory
infection
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Chapter 2 – Materials and Methods
2.1 Phylogenetic Analysis of HAdV-E4 WGS
WGS for 15 new HAdV-E4 strains were determined by next generation
sequencing techniques in collaboration with Gabriel Gonzalez and Hidemi
Watanabe at Hokkaido University and Daryl Lamson at the Wadsworth Center,
New York State Department of Health, using the Ion Torrent (described by Kaján
and colleagues (20)) and MiSeq (as previously described by Kajon and
colleagues (128)) platforms, respectively. An additional 32 WGS (for 30 unique
strains) were retrieved from the NCBI GenBank database. Two WGS for strains 1
(RI-67) and 2 (CL68578) are included in this analysis. Accession numbers for all
WGS are listed in Table 4. The accession numbers for WGS of SAdV strains are
as follows: SAdV23 (AY530877), SAdV24 (AY530878), SAdV25 (AF394196 and
FJ025918), SAdV26 (FJ025923), SAdV30 (FJ025920), SAdV36 (FJ025917),
SAdV37 (FJ025921 and FJ025919), SAdV38 (FJ025922), SAdV39 (FJ025924),
and ChAdV-Y25 (JN254802; note: this strain was isolated in 1969 by Hillis and
Goodman (171) before the AdV field standardized the naming scheme for AdV
isolates from non-human primates (NHP)). Accession numbers for HAdV-B WGS
used in phylogenetic analysis are as follows: HAdV-B3 (DQ086466), HAdV-B7
(KF268134), HAdV-B 1 (AF532578), HAdV-B14 (FJ822614), HAdV-B16
(JN860680), HAdV-B34 (AY737797), HAdV-B35 (AY271307), HAdV-B55
(FJ643676), HAdV-B66 (JN860676), HAdV-B68 (JN860678), and HAdV-B79
(LC177352).

27

Alignments of WGS were performed using MAFFT V7.388 in the
Geneious v11.1.4 suite (Biomatters, https://www.geneious.com). ClustalW V2.1
was used for alignments of protein sequences or short nucleotide sequences in
Geneious. Average percent sequence identity was calculated by first aligning
sequences using the MAFFT algorithm in Geneious, then analyzing the distance
using MEGA X v10.0.5 (172). Average percent identity is reported with the
standard deviation calculated by Microsoft Excel. Percentage of genomic
guanine-cytosine content (%G+C) was calculated by Geneious and reported with
the standard deviation calculated by Excel. SAdV26 was deposited in GenBank
as an unannotated genome in 2009 (114). Prediction of SAdV26 ORFs was
accomplished by comparison with WGS from the SAdV25 (AF394196) and the
CL68578 (AY594254) strains.
Phylogenetic trees were constructed using MrBayes v3.2.7 (173) using the
general time-reversible substitution model with heterogeneity among sites,
modeled under a gamma distribution and allowing for a proportion of invariable
sites (GTR+Γ+I) as a substitution model, chosen as the model with the highest
corrected Akaike information criterion (AICc) calculated with jModelTest 2 for the
multiple sequence alignments. Trees were inferred with chain lengths of 10 6
states to assure convergence.
Simplot, a sequence similarity plotting tool (174), was used to identify
conserved and divergent regions along the genomes of the examined HAdV-E4
strains. WGS were first aligned with MAFFT then imported into Simplot. A
similarity plot was generated in Simplot v3.5.1 using the following parameters:
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200 nucleotide sliding window, 20 nucleotide step size, GapStrip On, and Kimura
distance model and Ts/Tv=2.0.
To test whether the HAdV-E4 genomic sequence data set provided
enough data to analyze the temporal signal, the clock-likeness was checked by
performing a linear regression between the parameters “root-to-tip divergence”
and “sampling data” with TempEst (175). Time to the most recent common
ancestor (tMRCA) was estimated by independent Bayesian Markov Chain Monte
Carlo coalescent analyses by BEAST v2.4.6 (176) with chain lengths of 5 x 107
to assure an effect sample size of > 300 in all parameters of the models.
Analyses were performed separately for WGS in the two groups of strains
identified as p-like (PG I) and a-like (PG II). The tMRCA was also estimated for
both groups by analyzing a combination of CDS alignments excluding those
suspected to have resulted from recombination events. The strict and relaxed
clock models were considered for the data sets. The coalescent constant,
exponential, and Bayesian skyline models were considered for the populations
(177, 178). The marginal likelihood of the combination of models and data was
estimated in BEAST and with the Path-Sampler. Additionally, the distribution of
the mutation rate for the two PGs was analyzed in TreeStat v1.2 in BEAST
software suite.

2.2 Cell Culture
The A549 cell line (human type II alveolar epithelial cells, ATCC CL-185)
was cultured in A549 Growth Medium (Minimum Essential Medium (MEM, Gibco)
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supplemented with 8% (v/v) heat-inactivated New Born Calf Serum (HI-NBCS,
Rocky Mountain Biologicals), 1.5 g/ml Na2CO3 (Amresco), 2 mM L-glutamine
(Corning), 10 U/ml penicillin (Corning), 10.0 μg/ml streptomycin (Corning), and
25.0 mM HEPES (Corning)). The Calu-3 cell line (human airway epithelial cells,
ATCC HTB-55) was cultured in Calu-3 Growth medium (RPMI-1640 medium
(Corning) supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals), 2.0
mM L-glutamine, 10.0 U/ml penicillin, 10.0 μg/ml streptomycin, and 25 mM
HEPES). The Cotton Rat Lung Cell (CRLC) line (ATCC PTA-3930, currently
discontinued) was cultured in CRLC Growth medium (Minimum Essential
Medium (MEM, Gibco) supplemented with 10% (v/v) heat-inactivated Fetal
Bovine Serum (Atlanta Biologicals), 1.5 g/ml Na2CO3 (Amresco), 2.0 mM Lglutamine (Corning), 1mM sodium pyruvate (Corning), 10.0 U/ml penicillin
(Corning), 10.0 μg/ml streptomycin (Corning), and 25.0 mM HEPES (Corning)).
For virus infections, cells were cultured in Infection Medium (identical to growth
medium except the serum was reduced to 2%).

2.3 Viruses
A list of virus strains selected for the in vitro and in vivo studies (see
Chapter 4) are found in Table 5 (Note: NHRC 25562 is 99.9% identical to Strain
31 in Table 4). Virus stocks were produced in A549 cells maintained in A549
Infection Medium (identical to A549 Growth Medium, except for the
supplementation of 2% (v/v) NBCS). The infections were harvested by 3 rounds
of freeze/thaw cycles. For elimination of the membrane fraction, cell lysates were
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extracted with dd-H2O-saturated chloroform at a final concentration of 5%. The
upper phase was removed and vented overnight to remove the last traces of
chloroform. Adenovirus stocks were then aliquoted and titered by plaque assay.
The 4p CL68578 vaccine strain was derived from the pVQ WT #11183
genomic clone (ABL, Inc. through an MTA with the NIH). Briefly, the genomic
clone was released from the bacterial plasmid by PacI digestion and 1.0 μg of
linearized HAdV-E4 DNA was transfected into A549 cells using the Effectene
Transfection Reagent (Qiagen) following the manufacturer’s recommendations.
The transfected cells were then treated as infected cells. Infectious virus was
passaged minimally in A549 cells to make the stock virus using the procedure
described above.

2.4 Animals
Cotton rats (Sigmodon hispidus) used in this study were obtained from an
inbred colony at Sigmovir Biosystems Inc. (SBI). Animal studies were performed
after approval from SBI’s Institutional Animal Care and Use Committee. Animals
were housed in large polycarbonate cages and fed a diet of standard rodent
chow and water. Four-week-old female cotton rats were inoculated with 5x106
plaque forming units (PFU) of either the HAdV-E4 CL68578 or NHRC 42606
strain in each naris under isoflurane anesthesia. Mock-infected animals were
inoculated in the same manner with chloroform-extracted supernatants of A549
cells maintained in A549 Infection Medium. Cotton rats were sacrificed at 1, 2, 3,
and 6 days post infection (dpi) by CO2 asphyxiation. Animals were dissected, and
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the following lung lobes were used for downstream analysis: left lobe, molecular
viral load; left lingular lobe, mRNA reverse transcription for cytokine gene
expression; and right lung, histopathology. All lung lobes (except for the right
lobe, see Histological Analysis below) were snap frozen in liquid nitrogen and
stored at -80°C until processing.

2.5 Plaque Assay
A549 cells were grown to confluence in 6 well plates, and 0.1 ml of serially
diluted virus (diluted 1:10 in 1x PBS) were used to inoculate a single well. The
diluted virus was incubated at 37°C at 5% CO2 for 1.0 hour with periodic rocking.
The monolayer was then overlaid with a solution consisting of equal parts of
1.4% (w/v) Low Melt Agarose (G-BioSciences) and 2x MEM (Gibco)
supplemented with 4% (v/v) HI-NBCS, 4.0 mM L-glutamine, 20.0 U/ml penicillin,
20.0 μg/ml streptomycin, and 25mM MgCl2. At 7 dpi, infected A549 monolayers
were fixed with formaldehyde (final 1% formaldehyde (Sigma), 0.15M NaCl) and
stained with crystal violet (EMD-Millipore Sigma).

2.6 Plaque Development Assay
A549 cells were seeded in 15mm x 60mm dishes to be confluent on the
day of infection. Stocks were diluted in 1x PBS so that approximately equal
number of PFUs of each strain were used to inoculate each dish in biological
triplicate. Growth medium was aspirated, and the cells were inoculated with
diluted virus and synchronized on ice for 10 minutes. Inoculated cells were then
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incubated for two hours at 37°C 5% CO2. Following absorption, 5.0 ml of overlay
medium (described above) were added and allowed to solidify at room
temperature (RT), then incubated at 37°C 5% CO2. At 3 dpi, an additional overlay
(prepared as previously described, except with the addition of neutral red (JT
Baker Chemicals) at a final concentration of 0.0015%) was added, allowed to
solidify at RT, and then incubated at 37°C, 5% CO2. Starting a 4 dpi, plaques
were counted daily using a lighted background and marked with a pen. The
assay was terminated when no more plaques developed. The data are presented
as % final titer (total number of plaques for a given day divided by the total
number of plaques at the end of the assay) on each day.

2.7 Plaque Size Assays
A549 cells in 6 well plates were infected with approximately 20-40 PFU of
each virus strain. After absorption for 1 hour at 37°C and 5% CO 2 with occasional
rocking, the infected monolayers were overlayed as described above. At 7 dpi,
plaque morphology was photographed using an CKX41 microscope (Olympus)
with the Infinity 2 digital camera (Teledyne Lumenera). The images were
captured using the Infinity Capture software V6.5.4 (Teledyne Lumenera). The
plaque assays were then fixed and stained as indicated above.

2.8 Growth Curves
A549 cells seeded in 10mm x 35mm cell culture dishes and grown to 80%
confluence were inoculated with HAdV-E4 strains at a multiplicity of infection
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(MOI) of 1.0 PFU/cell, incubated on ice for 10 minutes, then absorbed for one
hour at 37°C and 5% CO2 with periodic rocking. Unbound virus was removed by
aspiration and the infected cell monolayers were washed twice with 1x PBS.
Cells were then replenished with A549 Infection Medium and incubated at 37°C
with 5% CO2. At various times post infection, infected cell monolayers were
frozen at -80°C and subjected to a total of three rounds of freeze/thaw cycles.
Cell debris was pelleted at 300 xg for 10 minutes and infectious virus titers were
determined by plaque assay as described above.

2.9 Dissemination Assays
A549 cells were seeded on 48 well dishes to be 100% confluent at the
time of infection. Growth medium was aspirated off, and the cells were inoculated
with 100 μl of virus stock diluted in 1x PBS at MOIs of 10.0, 1.0, 0.1, 0.01, and
0.001 PFU/cell, then set on ice for 10 minutes. The inoculated cells were then
incubated at 37°C and 5% CO2 for 1.25 hours. The inoculum was then removed
by aspiration, and the cells were washed twice with 1x PBS, then replenished
with A549 Infection Medium and incubated at 37°C and 5% CO 2. At 7 dpi, the
cells were fixed with 1% formaldehyde diluted in 0.15M NaCl, then stained with
crystal violet.

2.10 Cell Viability
Cell viability was assessed by lactate dehydrogenase (LDH) release from
infected cells into the cell culture medium using the CytoTox 96 Non-radioactive
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Cytotoxicity Assay Kit (Promega). Briefly, A549 cells were seeded in 48 well
plates to be confluent at time of infection. Cells were inoculated with virus diluted
in 1x PBS at a MOI of 1.0 PFU/cell in biological triplicate and incubated on ice for
10 minutes. Inoculated cells were then incubated at 37°C for 1 hour at 5% CO 2.
The inoculum was then removed, and the cells were washed twice with 1x PBS,
then replenished with A549 Infection Medium. At 1, 2, and 3 dpi, the supernatant
was removed and spun at 300 xg for 10 minutes. LDH activity was then
assessed according to the manufacturer’s directions (with the suggested
controls) in technical quadruplicate. The data are reported as mean absorbance
(490nm) ± the standard error of the mean (SEM).
As an alternate approach, intracellular ATP levels were measured as a
surrogate for cell viability using the CellTiter-Glo 2.0 kit (Promega) according to
the manufacturer’s specifications. Briefly, A549 cells were seeded in 96 well
dishes to be 75% confluent on the day of infection. Cells were inoculated at a
MOI of 10.0 PFU/cell with virus diluted in 1x PBS or mock-infected with 1x PBS
in biological quadruplicate and incubated on ice for 10.0 minutes. The inoculated
cells were then incubated at 37°C for 2 hours at 5% CO2. The inoculum was then
removed, and the cells were washed twice with 1x PBS, then replenished with
50.0 μl of A549 Infection Medium. At various times post infection, ATP levels
were measured by adding an equal volume of CellTiter-Glo 2.0 reagent to each
well, mixing on an orbital plate shaker at 2000 rpm for 2.0 minutes, then
incubating at RT for 10.0 minutes. Relative luminescent units were then
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measured using a Luminoskan Ascent Type 392 (ThermoFisher Scientific). The
data are reported as mean relative luminescence units ± SEM.

2.11 Polarization of Calu-3 Cells and Measurement of Transepithelial
Electrical Resistance (TER)
Calu-3 cells were seeded onto transwell inserts (0.4μm pore size,
Corning) at a density of 5.0x105 cells/well, and Calu-3 Growth Medium was
added to both the apical and basal compartments. Two days post seeding, the
cells were washed with 1x PBS++ (Dulbecco's Phosphate-Buffered Saline with
Magnesium and Calcium, Gibco). All liquid was then removed from the apical
chamber, and the cells were grown at an air/liquid interphase for 10 days with
medium changes every 48 hours.
Polarization of Calu-3 cells was evaluated by measuring the TER using a
Millicell ERS meter (Millipore). Before measurement, the medium was removed
from the basal compartment, and 1x PBS++ was added to the basal and apical
compartment, then allowed to equilibrate at 37°C 5% CO2 for 1.0 hour. TER was
then measured using chopstick electrodes. Cells were considered polarized
when TER values were between 500-600 Ωcm-2.

2.12 Infection of Polarized Calu-3 Cells
For infection of Calu-3 cells, medium was removed from the basal
compartment, and Calu-3 Infection Medium was added. Virus diluted in 1x
PBS++ was then added to the apical compartment at a multiplicity of infection of
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10.0 PFU/cell. After absorption at 37°C, 5% CO2 for 1.0 hour, the inoculum was
removed, and the cells were washed with 1x PBS++. All liquid in the apical and
basal compartments was removed, and fresh Calu-3 Infection Medium was
added to the basal compartment. The cells were then incubated at 37°C, 5%
CO2. At 1-3 dpi, the infected cells were processed by washing the apical
compartment twice with a total of 400 μl of 1x PBS ++. Infectious virus titers in
the apical wash were then determined by plaque assay.

2.13 Assessment of Pulmonary Viral Load in infected Cotton Rats
Frozen left lobe sections were weighed then transferred into a prechilled
2.0 ml SafeLock tube (Eppendorf) containing a prechilled 5mm stainless steel
bead (Qiagen, previously sterilized with 70% ethanol) and 1.0 ml of serum-free
A549 growth medium. The samples were then homogenized using the
TissueLyser II apparatus (Qiagen) at 30 hz for 30 seconds for a total of three
cycles, chilling on ice between each step. The samples were then spun at 16,000
xg for 10.0 minutes, and the supernatant was aliquoted into three separate tubes
of equal volume.
DNA was extracted from 200.0 μl of the supernatants from lung
homogenates using the MagNA Pure Total Nucleic Acid Isolation protocol on the
MagNA Pure LC 2.0 instrument (Roche Diagnostics). 5.0 μl of the Simplexa
Extraction and Amplification Control (DiaSorin Molecular) were added to each
sample prior to extraction. Samples were eluted in a volume of 50.0 μl.
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The real-time PCR assay was developed on the LIAISON® MDX
instrument (DiaSorin Molecular) using the Universal Disc (96 well, DiaSorin
Molecular) and DiaSorin Molecular Adenovirus analyte-specific reagents. The
Adenovirus 3’ hexon primer pair and the Adenovirus 5’ hexon primer with a FAMlabeled integrated probe were used to amplify and detect a conserved region of
the HAdV hexon gene. Internal Control (SEAC) Primer Pair with a Quasar® 760labeled integrated probe was used to amplify and detect the SEAC DNA
fragment. The 5’ and 3’ hexon primer pairs are a proprietary bi-functional
fluorescent primer-probe set targeting the 3’ and 5’ regions of the HAdV hexon
gene. Each reaction contained 4.0 μl of 2.5x Universal Master Mix, 0.2 μl
Adenovirus 3’ Hexon primer pair, 0.2 μl Adenovirus 5’ Hexon primer pair, 0.2 μl
internal control primer, 0.4 μl water, and 5.0 μl extracted template for a total
reaction volume of 10μl. PCR amplification with real-time detection was
performed using the following cycling conditions: denaturation, 97°C for 120
seconds (1 cycle); denaturation at 97°C for 10 seconds, followed by
anneal/extension at 60°C for 30 seconds (40 cycles). Fluorescence was
measured at the end of each anneal/extension cycle with quantitative values
calculated by the LIAISON® MDS software. Standard curves were generated
from highly pure HAdV-E4 DNA extracted from either CL68578 (p-like vaccine
strain) or NHRC 42606 (a-like strain)-infected A549 cells using a slightly modified
version of the protocol developed by Shinagawa and colleagues (179). The
calibrator values ranged from 1.2x106 to 1.2x102 cp/ml (CL68578) and from
2.8x106 to 2.8x102 cp/ml (NHRC 42606). Each standard was extracted in
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singlicate with each extract amplified in quadruplicate in a single run. Quantitative
analysis was performed by the LIAISON® MDX Software. Standard curves were
used for all subsequent viral load determinations.

2.14 RNA Isolation and Reverse Transcription
Total RNA was extracted from the left lingular lobes using the RNAqueous
kit (ThermoFisher Scientific). Frozen lung sections were transferred from their
storage tube into a prechilled 2.0 ml SafeLock tube along with a prechilled,
previously sterilized 5 mm stainless stead ball. Lysis/Binding solution from the
RNAqueous kit (1.0 ml) was then added to each sample. The samples were then
homogenized using the TissueLyser II at 30hz for 30 seconds for a total of three
cycles, chilling on ice between each step. The samples were then spun at 16,000
xg for 2.0 minutes at 4°C. The supernatant was then collected, and total RNA
isolated using the RNAqueous kit according to the manufacturer’s
recommendations. Residual DNA was then removed from 20.0 μg of total RNA
using the TurboDNA-free kit (ThermoFisher Scientific). To ensure that
contaminating DNA was removed, PCR was performed with primers specific for
the rig/S15 gene (see Table 3) using the goTaq Flexi DNA polymerase
(Promega) using the following cycling conditions: 1 cycle of 95°C, 5 minutes; 50
cycles of 95°C for 30 seconds, followed by 57°C for 30 seconds, then 72°C for 30
seconds; 1 cycle of 72°C for 5 minutes. No PCR product was detected. Reverse
transcription was then performed on 1.0 μg of DNAse-treated RNA using the
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RetroScript Reverse Transcription kit (ThermoFisher Scientific) following the
manufacturer’s recommendations.

2.15 Analysis of Cytokine Gene Expression in the Lungs of HAdV-E4Infected Cotton Rats
cDNA (described above) was subjected to real-time quantitative PCR (RTqPCR) analysis using primers described previously (180–182) and shown in
Table 3. RT-qPCR reactions were carried out using 3.0 μl of cDNA template and
the QuantiFast SYBR Green PCR kit (Qiagen) using the MyiQ single color Realtime PCR instrument (Bio-Rad) using cycling conditions previously reported
(180–182). Relative quantification of PCR products was performed by
normalizing to β-actin using the ΔΔCT method. The data are presented as mean
fold induction ± SEM.
Table 3: Primers Used in the Analysis of Cytokine Gene Expression
Gene
Primer Sequence
Rig S/15 Forward 5’-TTC CGC AAG TTC ACC TAC C-3’
Reverse 5’-CGG GCC GGC CAT GCT TTA CG-3’
β-Actin
Forward 5’-GGC CAA CCG TGA AAA GAT GAC TC-3’
Reverse 5’-GTC CGC CTA GAA GCA TTT GCG-3’
IFN-β
Forward 5’-GCA GCA TTT CAG AAT GTC TAG AGC-3’
Reverse 5’-ATC TTA ATA AGT CTT CCC ATG G-3’
IL-6
Forward 5’-GGC ACA CTT AGG CAC AGC ATA CTC G-3’
Reverse 5’-CAC AAC TCC ATC TGC CCT CCA GGA-3’
MCP-1
Forward 5’-GAT GCA GTT AAT GCC CCA CTC ACC-3’
Reverse 5’-CAG TGG GAA ATG GAA GAG CAG AGG-3’
IP-10
Forward 5’-AAC CAG AGA GAA GCC GAT CA-3’
Reverse 5’-GGC CGA TAG TAA GCC ATG AA-3’
Rantes
Forward 5’-AGC AGC AAA TGC TCC AAC TT-3’
Reverse 5’-CCA GGC TCT GAA GAG GAC AC-3’
GRO-α
Forward 5’-GCA GGG GTT CAC TTC AAG AAC-3’
Reverse 5’-GGT GTT TCA GAA GCC AGC ATC-3’

40

2.16 Histologic Analysis
Dissected lungs (right lobe) were inflated with 10% neutral buffered
formalin, then immersed in formalin for fixation. The lungs were then paraffinembedded, sectioned, then stained with hematoxylin and eosin (H&E) at
Histoserv, Inc.. The stained lung sections were then scored blindly at SBI on a
scale of 0 to 4 (absent, minimal, mild, moderate, and marked) for the following
indices of pulmonary inflammation: peribronchiolar inflammatory cell infiltration
(inflammatory cell infiltration around the bronchioles), perivascular inflammatory
cell infiltration (inflammatory cell infiltration around the small blood vessels),
interstitial pneumonia (inflammatory cell infiltration and thickening of alveolar
walls), and alveolitis (cells within the alveolar spaces) (183).

2.17 Statistical Analysis
All statistics (unless otherwise noted) were calculated using GraphPad
Prism v8.1.0 for Microsoft Windows (GraphPad, https://www.graphpad.com).
Figure legends indicate the specific statistical test used as well as the number of
replicates. p values < 0.05 were considered statistically significant. The sample
size for animal experiments was determined by power analysis using G*power
software v3.1.9.2 (184) specifically to observe differences in pulmonary
pathology scores. With an effect size of 1.5 pathology score units, a standard
deviation of the virus-infected groups of 1.0, and achieving <80% power with a
0.05 significance level, 6 animals were needed per group.
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Chapter 3 – Aim 1: To Characterize the HAdV-E4 Genetic Variability by
Examination of WGS of a Large Collection of Strains Isolated Worldwide
Between 1953 and 2015

3.1 HAdV-E4 Strains Cluster into Two Distinct Evolutionary Lineages
WGS of HAdV-E4 strains isolated in the United States and Japan were
combined with publicly available WGS to compile a total of 47 genomic
sequences from 45 unique HAdV-E4 strains from respiratory and ocular
specimens isolated between 1953 and 2015 that represent a diversity of genomic
variants and geographic locations (Table 4). Confirmation of genotype identity (plike or a-like) was carried out by in silico RFLP analysis (Table 4). Phylogenetic
analysis of WGS representing 45 different strains confirmed the previous
observation from Li and Wadell (149) that HAdV-E4 strains cluster into two
district evolutionary lineages (Figure 6), referred hereafter as phylogroups (PGs).
Phylogroup I (PG I) comprises p-like strains that are closely related to the
prototype strain RI-67, and Phylogroup II (PG II) comprises the a-like genomic
variants. Figure 6 also includes the SAdV members of HAdV-E, which bear
strong sequence homology to HAdV-E4, as well as members from HAdV-B.
Further analysis of WGS revealed differences in the percentage of genomic
guanine-cytosine content (%G+C) between PG I and PG II (see Table 4), which
further supports their distinctions as separate evolutionary lineages; PG I
genomes had a mean %G+C of 57.7% ± 0.013 and PG II genomes had a mean
%G+C of 56.3% ± 0.015. Furthermore, the average intra-PG I sequence identity
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to RI-67 was 99.84% ± 0.12, while the average intra-PG II sequence identity to
V0014 (strain 13, the earliest available PG II strain) was 99.88% ± 0.09.

Table 4: Origin and Genomic Characteristics of HAdV-E4 Strains Included in
the Analysis
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Figure 6: HAdV-E4 comprises two distinguishable phylogroups
Phylogenetic tree of whole genome sequences of HAdVs of species B, E, and
SAdVs of species HAdV-E. Bayesian posterior probability support is shown next
to the branches.

3.2 Estimation of the Time to the Most Recent Common Ancestor for HAdVE4 Strains
Available records show 12 years between the first documented isolation of
a p-like HAdV-E4 strain (RI-67, USA, 1953(2)) and the first documented isolation
of an a-like strain (strain BC 129, China,1965 (149, 153)). As these dates are not
necessarily reflective of real timelines of circulation, the tMRCA was estimated. A
Bayesian approach using the BEAST software package was used to calibrate the
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tree with isolation year of each strain. An exponential molecular clock was used
to demonstrate that both PGs diverged from the common ancestor approximately
602 years before the present (ybp), or in 1413 in the absolute time scale with
2015 as the most recent calibration date (Figure 7). This analysis also showed
that PG II had a slightly higher mutation rate than PG I (3.69 x 10-5 compared to
3.24 x 10-5 mutations/site/year for PG II and PG I, respectively). The results
suggest that PG I strains are descendants from a strain circulating approximately
91 ybp (1924 in the absolute time scale) in the 95% highest posterior density
range (95% HPD) [67, 144ybp] while PG II strains descended from an ancestral
strain circulating approximately 54 ybp (1961 in the absolute time scale) in the
95% HPD [40, 84 ybp] (Figure 7).
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Figure 7: Bayesian estimation of the time to the most recent common
ancestor for HAdV-E4 strains in PG I and PG II
The phylogenetic tree is annotated in the branches with years before the present.
The 95% highest posterior density (HDP) ranges for tMRCAs of all sequences
are shown for both phylogroups between brackets.
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3.3 Detailed Analysis of Sequence Diversity Between PG I and PG II
On average, PG I genomes were found to be ~94.5 % identical to
genomes in PG II. Interestingly, this level of genetic relatedness is comparable to
that between any two different HAdV genotypes of the same species: 94% ± 5 for
HAdV-B; 96% ± 1 for HAdV-C; and 94% ± 1 for HAdV-D, many of which are also
serologically distinguishable. An analysis was conducted using Simplot to identify
conserved and divergent regions along the genomes of PG I and PG II strains. A
representative plot including three genomic variants from each PG is shown in
Figure 8. Nucleotide similarity versus nucleotide position is plotted for the HAdVE4 WGS compared with the query strain, RI-67. WGS closely related to the RI-67
WGS will plot higher on the Y axis, while those more distantly related will plot
further down on the Y axis. This analysis clearly shows differences in genetic
content between PG I and PG II strains. The most striking differences between
PG I and PG II sequences map to the ITRs and E3, although additional
mutations with potential to result in phenotypic differences relevant to
pathogenesis are found in multiple genomic loci, including E1, VA RNA, L3, and
L4 as described and discussed in detail below.
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Figure 8: Analysis of genomic sequences of representative strains of PG I
and PG II for regions of divergence and similarity
A similarity plot was generated using the Simplot software comparing HAdV-E4
strains representing the major genomic variants with the RI-67 as the query
strain. MAFFT was used to align WGS prior to Simplot analysis with the following
parameters: window size, 200 nucleotides; step size, 20 nucleotides; GapStrip,
on; distance model, Kimura.

3.3.1 Inverted Terminal Repeat (ITR)
The analysis of 12 WGS in PG I and 33 WGS in PG II confirmed previous
reports of differences in the ITR sequences between the two lineages of HAdVE4 genomic variants including differences in length (115, 155). PG I genomes
had an average ITR length of 113.8 bp ± 3.4 and an average intragroup percent
identity of 98.6% ± 1.8, whereas the average length for PG II genomes was
206.5 ± 2.7 and the intragroup percent identity was 99.6% ± 0.3. As shown in
Figure 9, the ITR sequences of PG I genomes have a higher sequence identity
with SAdV26, while the PG II sequence is closer to that of HAdV-B16. It has
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been suggested that the ancestor PG II strain obtained this unique ITR through
intraspecies recombination events (115, 155).

Strain 27
Strain 27
HAdV-B16
Strain 2
SAdV26

89.74%
61.34%
63.03%

HAdV-B16
89.74%
58.47%
64.41%

Strain 2
61.34%
58.47%

SAdV26
63.03%
64.41%
78.81%

78.81%

Figure 9: Percent identity matrix for the ITR region among PG I and PG II
strains with other AdVs
The ITR region for Strains 1 and 27 (representing PG I and PG II, respectively)
as well as HAdV-B16 and SAdV26 was aligned using ClustalW in the Geneious
software package, and the percent identity was calculated.

This analysis also confirms the differences between nuclear factor
recognition sites between PG I and PG II ITR sequences originally identified by
Dehghan and colleagues (115, 185). Examination of WGS from 45 HAdV-E4
strains did not reveal any intragroup differences in the NFI or NFIII sites among
PG II genomes. Interestingly, a subset of the PG I strains (strains 9-11) shared
the NFIII binding motif (5’-TATGTAAATAA-3’) with PG II strains; this motif was
different from that of the prototype strain (5’-TATGCAAATAA-3’).
Differences in the terminal 8 bp of the ITR sequences have been noted for
PG II strains (155). In the present analysis, only one strain examined had the 5’CTATCTAT-3’ sequence (strain 1, RI-67 reported by Paurkayastha and
colleagues (157)), while most others carried the 5’-CATCATCA-3’ sequence
(Figure 10). Interestingly, Hang and colleagues reported RI-67 to carry the 5’CATCATCA-3’ ITR sequence (KX384994, (152)). This discrepancy has been
noted in the literature (186) and may be due to variation in the stocks of the RI-67
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virus (ATCC VR-4 (5’-CTATCTAT-3’) submitted by Maurice Hilleman compared
to ATCC VR-1572 (5’-CATCATCA-3’) submitted by Wallace Rowe), as RI-67
has been passaged continuously in culture since its isolation more than 60 years
ago. Figure 10 also shows a minority of strains had noncanonical sequences (5’ATAATATA-3’, 5’-AATAATAT-3’, 5’-GCATCATC-3’, and 5’-CAATAATA-3’).
These differences may be genuine or might be the result of different ITR
sequencing methodologies; the authors who published these sequences do not
specifically discuss the ITR regions (128, 152).

Figure 10: Terminal 8 bp sequence in HAdV-E4 ITR
The HAdV-E4 ITR was analyzed from WGS data from 45 HAdV-E4 strains. Note
that strain 1 (RI-67) is listed twice as the two WGS available report differences
in this region.

Lastly, the NHRC 22650 strain (#29 in Table 4) was observed to have a
194 bp insertion by duplication of the neighboring genomic loci adjacent to the
right hand ITR. The impact of this unique feature on viral replication is unknown.
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3.3.2 Early Region 1
Early region 1A (E1A)
While the genomes of PG I encode 28.0 kDa (257 aa) and 24.6 kDa (226
aa) polypeptides, the PG II genomes encode slightly shorter polypeptides of 27.0
kDa (246 aa) and 23.5 kDa (215 aa), respectively. The predicted polypeptide
sequences encoded by all examined genomes in PG I are identical, while PG II
sequences are slightly different and on average 87.8% similar to those of the
prototype strain RI-67 in PG I. The most striking difference between the E1A
polypeptides encoded by the two PGs is an 11 amino acid deletion (aa 82-94)
between the conserved regions CR1 and CR2 found in all examined PG II
genomes (Figure 11). The deletion includes a leucine at position 91 and a
threonine at position 93 which Avvakumov et al. described as highly conserved
amino acids in the E1A proteins encoded by members of species HAdV-B,
HAdV-D, and HAdV-E, although no function has been assigned to these residues
(187). Interestingly, the 11 amino acid deletion was not present in any of the
examined genomes of simian members of species HAdV-E. Conservation of the
E1A polypeptide sequences among HAdVs varies between species (44), and in
general most functional studies have focused on the function of E1A for HAdV-C.
Examples of sequence variation resulting in differences in function have been
noted (188, 189), and additional work in identifying functional differences among
species-specific E1A proteins is needed.
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Figure 11: Sequence divergence of the HAdV-E4 large E1A polypeptide
Large E1A polypeptide sequences from HAdV-E4 strains representing the
spectrum of genetic diversity (strains 1, 2, 11, 12, 27, 31, and 37) were aligned
using ClustalW. Amino acids highlighted in red and green represent CR1 and
CR2 sequences, respectively. Amino acids highlighted in purple represent
evolutionary conserved amino acids not present in PG II sequences.

Early region 1B (E1B)
The predicted polypeptide sequence for E1B 19K is conserved among
members of PG I as well as among members of PG II with an 89.6% inter-PG
sequence identity. There are eight non-synonymous mutations that result in
amino acid changes. Additionally, there is a 33 nucleotide (11 amino acid) inframe insertion among PG II members located in the shared coding region for
E1B 19K and E1B 55K. This insertion is also present in the coding sequence for
E1B 19K in the genomes of SAdV23, SAdV24, SAdV25, SAdV26, and ChAdVY25, although only 5 of the 11 amino acids are conserved within PG II
sequences (Figure 12).
The predicted sequences for E1B 55K encoded by all examined PG I
strains were identical and the sequences for E1B 55K encoded by PG II strains
had an average sequence identity to the prototype PG I strain RI-67 of 93.6%. In
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addition, all PG I strains are characterized by an 11 amino acid insertion at their
N-terminus arising from the 33 nucleotide insertion event described above for
E1B 19K (Figure 12). This region of the protein is characterized by low sequence
homology to other E1B sequences from other HAdV species (187), and further
work will be needed to identify the functional impact of this deletion as well as
other mutations distinguishing the E1B proteins encoded between PG I and PG II
strains.

Figure 12: HAdV-E4 sequence divergence in the shared E1B coding region
Cartoon schematic of the E1B coding region with flanking nucleotide positions
(middle). The translated sequence for E1B 19K (above) and E1B 55K (below)
demonstrating the 11 amino acid insertion in PG II strains. Strains 1, 2, 11, 12,
27, 31, 37, and SAdV26 are shown as representative strains.

3.3.3 Virus-associated RNAs
Consistent with the original observations reported by Kidd and colleagues
(156), all PG II genomes examined in this study exhibit a 65 bp deletion in VA
RNAII starting at position 10593 (relative to prototype strain RI-67) that partially
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ablates the promoter element A, and that results in the complete loss of promoter
element B. VA RNAII is predicted to not be expressed in PG II strains (156), as
VA RNAs are not expressed in viruses that carry mutations in these promoter
elements (190, 191). The genomes of a subset of PG I strains (#8, 9, 10, and 11)
have an additional 20 bp deletion starting at nucleotide position 10639 that
involves the last two nucleotides in the sequence of the promoter element B
(Figure 13).

Figure 13: HAdV-E4 VA RNAII sequence
The VA RNA II sequences for strains 1, 2, 11, 12, 27, 31, and 37 were aligned
using ClustalW. Elements A and B are shown in red and purple boxes,
respectively.

3.3.4 Hexon Hypervariable Region 1-7
PG I and PG II strains had an average of 99.7% and 97.1% sequence
identity with the RI-67 strain, respectively. The analysis focused on hypervariable
regions 1-7 of the hexon gene (HVR 1-7) which encode the serotype-specific
residues displayed in loops 1 and 2 of the hexon capsid protein that project from
the surface of the virion (192). No difference in HVR 2 was observed among PG I
and PG II strains (data not shown). Several nonsynonymous point mutations in
HVR 1 and 3-7 that distinguish the genomes of PG I and II were identified.
Interestingly, a subset of PG II strains (strains 7-11), typed as the 4p4 genome
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variants, exhibited a 4 amino acid deletion in HVR 3. A summary of the genetic
differences between PG I and PG II sequences are found in Figure 14.

Figure 14: Amino acid differences identified in the HVR 1 and 2-7 of the
hexon polypeptide among examined strains of PG I and PG II

3.3.5 Late Region 4 100K
The predicted L4-100K amino acid sequence encoded by PG I strains was
on average 99.8% identical to that of RI-67 whereas the PG II sequence was on
average 96.3% identical. PG I strain #12 described by Kajon and colleagues
exhibited a single glutamine insertion (nucleotides CAG) at amino acid position
20 (128). Several differences were identified between PG I and PG II sequences
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in the glycine-arginine rich (GAR) C-terminal region of L4-100K. GAR regions are
sites of arginine methylation with the common consensus sequence arginineglycine-glycine (RGG) (193, 194). In HAdV-C5, the GAR region contains three
RGG repeats as well as other arginines that are post-translationally methylated.
Mutations of these arginines in HAdV-C5 L4-100K interfere with the protein’s
interactions with late viral transcripts, potentially disrupting the role of L4-100K in
hexon trimerization and preventing shuttling of L4-100K to the nucleus, ultimately
resulting in decreased viral replication (195, 196). The GAR region for PG I strain
RI-67 and its conservation among HAdV species was described by Iacovides and
colleagues (195). Comparisons of PG I and PG II sequences identified a 5 amino
acid deletion (glycine-glycine-glycine-arginine-serine) in all PG II strains between
amino acid positions 755 and 761 (relative to RI-67) that disrupts the third RGG
repeat in the GAR region (Figure 15). In addition, a single glycine insertion at
position 743 (relative to RI-67) is encoded in the genomes of all examined strains
of PG II creating an additional RGG tripeptide. The genomes of examined strains
#18, 23, 24, 26, 28, 33, 35, 37, 38, and 40 - 43 also exhibit a glycine to glutamic
acid replacement at position 717 that disrupts the consensus for an RGG
tripeptide (Figure 15). The methylation state of the L4-100K polypeptide for
HAdV-E4 has not been examined experimentally and further work will be needed
to elucidate whether the sequence differences detected at the C-terminus of L4100K between PG I and PG II strains affect viral replication.
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Figure 15: L4-100K GAR region for HAdV-E4 strains
The C-terminus of the L4-100K polypeptide was aligned using ClustalW. RGG
tripeptides are boxed in red. An additional RGG tripeptide found only in PG II
sequences are boxed in purple.

3.3.6 Early Region 3
In the same location as HAdV-C E3-11.6K encoding ADP (69), the E3
region of members of species HAdV-E encodes two or three CR1 genes (11, 68)
of unknown function. As shown schematically in Figure 16A, while the genomes
of SAdV of species HAdV-E encode three CR1 genes designated CR1β, CR1γ
and CR1δ (115, 157, 186), CR1γ is absent in the genomes of both HAdV-E4
PGs. As originally reported by Jacobs and colleagues, a vestigial E3 CR1γ
sequence lacking an initiating ATG and splice acceptor site is present in the
genomes of PG I strains due to a 326 bp deletion starting at position 29,449
relative to the SAdV26 genome (186). A unique 318 bp deletion in this region
(starting at 29,603 in the SAdV26 genome) of PG II genomes results in a similar
vestigial sequence (Figure 16A). Additionally, while unlikely to be expressed, a
short evolutionarily unrelated 328 bp ORF that has been annotated as E3-6.3K
(197, 198) is present in this region for PG I strains. As a result of a 29 bp deletion
which introduces an early stop codon, the vestigial sequence is shorter in the
genomes of PG II strains, and the E3-6.3K ORF is significantly truncated (Figure
16A-B). Marked amino acid sequence differences resulting from non57

synonymous point mutations as well as from INDELs in the N-terminal
ectodomains of E3 CR1β and E3 CR1δ (Figure 16C-D) distinguish the genomes
of PG I and PG II and highlight the divergence of these two genes in HAdV-E4
from those encoded by the closest SAdV, SAdV26. These genes have very low
sequence similarity to any other homologous genes in the NCBI database, thus
making sequence-based prediction of biological activity and function challenging.

3.4 Summary of Findings for Aim 1
The analysis of WGS from 45 HAdV-E4 strains isolated worldwide
between 1953 and 2015 demonstrated that HAdV-E4 strains cluster into two
distinct evolutionary lineages: PG I comprises strains closely related to the
prototype strain isolated in 1953, and PG II comprises the a-like genomic
variants. These findings confirmed previous observations from the 1980s
analyzing PCRF from HAdV-E4 genomes (149) as well as data from more recent
studies analyzing small sample sets of WGS (115, 199). Bayesian analysis
estimated the time to the most recent common ancestor for the PG I and PG II
lineages at 602 ybp, indicating that these strains have been evolving
independently for a longer period of time than has previously been suggested
(155). Comparative analysis of PG I and PG II WGS revealed differences in
coding and noncoding regions that may affect viral replication and/or
pathogenesis.
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Figure 16: Genetic diversity in the E3 region among HAdV-E4 strains
(A) Schematic comparing the genetic content of the E3 region for SAdV26 and
PG I and PG II strains. Differences in the CR1γ region among members of HAdVE are noted: SAdV26 encodes a 22.6K ORF while PG I and PG II strains do not.
See text for details. (B) Top panel, alignment of the 5’ end of the 6.3K ORF of
PG I and PG II strains. Premature stop codon (TAG) is boxed in red. Bottom
panel, alignment of the predicted E3-6.3K polypeptide sequences of PG I and
PG II strains. Alignment of E3 CR1β (C) and E3 CR1δ (D) polypeptides for PG I
and PG II strains. Transmembrane regions are highlighted in purple.

3.5 Limitations of This Study
This bioinformatics study provides insight into the phylogenies and genetic
variability of a comprehensive collection of HAdV-E4 strains, but it does have
limitations. While the collection of strains used in this study is comprehensive, it
would benefit from the addition of historical WGS from HAdV-E4 strains that are
no longer available (for example, PG II strain BC 129 isolated in 1965, as well as
PG II strains isolated in Rome in 1975 and New York in 1978 (125, 147, 149,
153)). These historical strains would provide valuable historical points for
calibrating molecular clocks for Bayesian analysis of tMRCA.
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There may be more genetic differences between PG I and PG II strains
that may contribute to differences in in vitro and in vivo phenotypes that have yet
to be described. The genetic variability described in this study included
differences due to INDELs or mutations with a known impact on certain
phenotypes and is a valuable starting point for future studies examining the
impact of HAdV-E4 genetic variability on in vitro and in vivo phenotypes.
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Chapter 4 – Aim 2: To Evaluate the Contribution of HAdV-E4 Intratypic
Genetic Variability to in vitro and in vivo Phenotypes Relevant to
Pathogenesis.

4.1 Subaim 1: To Compare the Growth and Cell Killing Phenotypes of
HAdV-E4 PG I and PG II Genomic Variants in Cell Culture

4.1.1 Virus Strains Used in this Study
To examine the differences in the biological properties among HAdV-E4
strains, a panel of HAdV-E4 strains that represent the spectrum of described
genomic variants in PG I and PG II were selected (Table 5). These strains
included the prototype strain, RI-67 as well as the closely related vaccine
CL68578 strain (99.94% whole genome sequence identity to RI-67), and two
other prototype-like strains that have been previously described (128, 139): the
recently isolated vaccine-like strain NY-15-4054 (99.94% sequence identity to RI67) and strain NHRC 90339, a 4p4 variant (99.63% sequence identity to RI-67).
PG II strains that represent the 4a, 4a1, and 4a2 genomic variants (NHRC
25562, NY-12-27440, and NHRC 42606, respectively) were also included.
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Table 5: HAdV-E4 Strains Included in the Experiments
Conducted for Aim 2

4.1.2 HAdV-E4 PG I Strains Exhibit a Large Plaque Phenotype and an
Enhanced Cell-to-cell Spread Phenotype Compared to PG II Strains
The ability of HAdV-E4 strains to form plaques in A549 cells was
examined first. Progeny virions released from infected cells under a semi-solid
agarose overlay disseminate laterally to neighboring cells. Viruses with the ability
to effectively lyse the infected cell or replicate faster will form larger plaques,
while viruses deficient in these abilities will form smaller plaques (69, 87). A549
cells in 6 well plates were infected with PG I and PG II strains following the
traditional plaque assay protocol and fixed and stained with crystal violet at 7 dpi.
PG I strains were observed to form larger plaques than PG II strains (Figure 17).
Variability in plaque size was also observed among PG I strains; the CL68578
strain formed the largest plaques, while the NY 15-4054, RI-67, and NHRC
90339 strains have incrementally decreasing plaque size. All PG II strains formed
uniformly small plaques (compared to the CL68578 strain). Variation in plaque
size in a single strain of virus was also observed. For example, in Figure 17, the
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RI-67, CL68578, and NY-15-4054 strains forms both small and large plaques.
This has been noted in the literature, and may be due to variation in virus
infection or viral gene expression during infection (89, 200, 201). The analysis of
brightfield images of plaques at day 7 dpi showed no differences in plaque
morphology.

Figure 17: PG I strains have larger plaques compared to PG II strains
Plaque assays from PG I (RI-67, CL68578, NY-15-4054, and NHRC 90339) or
PG II (NHRC 25562, NY-12-27440, and NHRC 42606) strains were fixed and
stained with crystal violet at seven days post infection. Brightfield images of
plaque morphology are shown below plaque assays. This assay was
representative of three independent experiments.
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The rate at which plaques from PG I and PG II strains develop over time
was next examined as described for HAdV-C laboratory mutants (69, 87). The
data are presented as a percentage of the final titer, where the number of total
plaques counted on a given day is divided by the total number of plaques
observed on at the termination of the assay (day 25). It was observed that the
plaques for all PG I strains were visible one day earlier (day 4) than plaques from
PG II strains (day 5). In addition, a subset of PG I strains exhibited a faster rate
of plaque development than all others, namely the CL68578 and the NY-15-4054
strains, while plaques for all other strains developed at similar rates. At 10 dpi,
about 90% and 70% of plaques were visible for the CL68578 and NY-15-4054
strain, respectively. In contrast, on day 10 only 30-40% of plaques of all other
strains were visible (Figure 18). The faster rate of plaque development for the
CL68578 strain correlates with its larger plaque size shown in Figure 17.
Cytopathic effect (CPE) was examined at different multiplicities of infection
in submerged infected monolayers to evaluate the cell-to-cell spread phenotype
as described for HAdV-C5 mutants lacking or overexpressing the ADP gene
(202, 203). A549 cell monolayers were infected at MOIs ranging from 0.001 to
10.0 PFU/cell, then fixed at 7 dpi. PG II strains spread at a restricted rate
compared to PG I strains (Figure 19). PG II-infected cells stained with crystal
violet were still attached to the plastic at the MOI of 1.0 PFU/cell while no cells
were visible among monolayers infected with PG I strains. PG I strains had
similar spread phenotypes with the CL68578 strain showing the most extensive
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CPE at lower MOIs (particularly evident at 0.01 PFU/cell) compared to other
strains. These data are consistent with the plaque size phenotypes.
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Figure 18 The rate of plaque development is faster for certain PG I strains
compared to other examined strains
Plaques were counted every one to two days in plaque assays performed in
60mm dishes in biological triplicate. The total number of plaques observed on a
given day is plotted as a percentage of the total number of plaques observed on
the final day. This assay was representative of two independent experiments.
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Figure 19: PG I strains exhibited an enhanced spread phenotype in
submerged A549 cells
A549 cells were infected at MOIs ranging from 0.001 to 10.0 PFU/cell (shown in
rows on the left side of the plate) with PG I or PG II strains (labeled in columns
at the top of the plate). At 7 days post infection, cell monolayers were fixed and
stained with crystal violet. This assay was representative of two independent
experiments.

4.1.3 HAdV-E4 PG I Strains Exhibit Faster Replication Kinetics Than PG II
Strains
The large plaque phenotype in Figure 17 could either be an indication of
increased viral replication kinetics or enhanced cell lysis as a result of infection.
To compare the growth kinetics of PG I and PG II strains, monolayers of A549
cells were infected at a MOI of 1.0 PFU/cell and infectious virus was harvested at
12, 24, 48, and 72 hours post infection (hpi). Infectious virus yield was then
determined by plaque assay in A549 cells. Higher infectious virus yields were
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detected in PG I-infected monolayers at 24 hpi (Figure 20) while infectious virus
titers were similar at 48 and 72 hpi. This indicates that PG I strains have faster
replication kinetics among all examined strains at early times post infection.
Next, the kinetics of viral progeny release of select PG I and PG II strains
were assessed in a polarized lung epithelial cell model. Polarized Calu-3 cells
were infected apically at a MOI of 10.0 PFU/cell, and the infectious virus yield
from apical washes was determined by plaque assay in A549 cells. Higher
infectious virus titers were detected in the apical compartment of the PG I strain
CL68578-infected polarized Calu-3 wells at 48 and 72 hpi (Figure 21). This result
could be attributed to faster virus replication kinetics and/or lytic release from the
infected cell.
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Figure 20: PG I strains exhibit faster replication kinetics in vitro
Submerged A549 cell monolayers were infected with PG I or PG II strains at a
MOI of 1.0 PFU/cell in biological triplicate. Infectious virus yield was determined
for the indicated time points by plaque assay in A549 cells. This assay was
representative of two independent experiments.
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Figure 21: Increased infectious virus yield was detected in the apical
compartment from PG I-infected polarized Calu-3 cells
Polarized Calu-3 cells were infected apically at a MOI of 10 PFU/cell in biological
triplicate. At the indicated time points, apically released virus was determined by
plaque assay in A549 cells. This assay was representative of two independent
experiments.

4.1.4 Increased Cell Death Is Observed in Cells Infected with PG I Strains
Increased cell lysis is observed for HAdV-C genotypes, which encode
ADP, compared to ADP-null HAdV-C mutants (69). In these studies, cell lysis
correlated with plaque size. LDH activity from cell culture supernatants of PG Ior PG II-infected A549 cells was determined as a surrogate of cell viability. Viable
cells with intact membranes will not release LDH into the supernatant, whereas
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LDH activity can be detected from supernatants of cells undergoing apoptosis or
necrosis (204). A significant increase in membrane permeability (as evidenced by
the higher A490 reading) was observed in CL68578-infected cells compared to
the NHRC 42606-infected cells (Figure 22).

Figure 22: Higher levels of lactate dehydrogenase activity are detected in
the cell culture medium of CL68578-infected A549 cells than in NHRC
42606-infected A549 cells
A549 cell monolayers were infected at a MOI of 1.0 PFU/cell in biological
triplicate and cell lysis was assessed by determining lactate dehydrogenase
activity in the cell culture medium in technical quadruplicate. Statistical
significance was assessed by Student’s t test, *p < 0.05, ****p < 0.0001.

Intracellular ATP levels following HAdV-E4 infection of A549 cells were
measured as another surrogate for cell viability. The concentration of ATP is
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proportional to the amount of viable cells (205). A549 cells were infected at a
MOI of 10 PFU/cell, and intracellular ATP was measured at 96 hpi. Significantly
more viable cells were observed at late time points post infection for PG IIinfected cells than for PG I-infected cells. While the ATP levels from PG IIinfected cells were relatively similar at 96 hpi, variability was observed among PG
I-infected cells. Lower levels were observed in RI-67- and CL68578-infected cells
compared to NY-15-4054- and NHRC 90339-infected cells (Figure 23). These
data examining cell viability reveal increased cell killing by PG I strains compared
to PG II strains.

Figure 23: A549 cells infected with PG II strains remain viable for longer
periods of time
A549 cells were infected at a MOI of 10.0 PFU/cell in biological triplicate. At 96
hours post infection, intracellular ATP concentration as a surrogate for cell
viability. Statistical significance was assessed by one way ANOVA analysis, F(7,
24) = 140.9, p < 0.0001. Tukey’s posthoc comparisons to mock-treated cells
revealed a significant difference, **** p < 0.0001.
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4.1.5 Summary of Results for Subaim 1
In summary, PG I and PG II strains have distinct in vitro growth and cell
killing phenotypes. PG I strains had: 1. faster replication kinetics in A549 cells at
early time points post infection, 2. increased viral progeny release in polarized
Calu-3 cells, 3. larger plaque sizes, 4. an enhanced cell killing phenotype, and 5.
an enhanced cell-to-cell spread phenotype compared to PG II strains.

4.1.6 Limitations of this Study
This study provides new data demonstrating that PG I and PG II strains
have distinct in vitro phenotypes, however there are more questions that require
attention. Firstly, the mechanisms underlying the observed phenotypes are not
known and require further examination. For example, it is not known if PG I
viruses have faster replication kinetics due to enhanced infectivity (more
infectious virus particles enter cells) or due to differences in regulation of virus or
cellular genes during infection. It is also not clear why PG II-infected cells remain
viable for longer periods of time. Preliminary experiments examining apoptosis
markers in PG I and PG II-infected cells were inconclusive (data not shown).
Lastly, evaluation of these phenotypes in a broader range of cells lines, including
primary lung epithelial cell lines, is needed. An exploratory experiment
demonstrated an enhanced CPE phenotype in PG I-infected immortalized human
bronchial epithelial cells (HBEC-2 cell line (206)) compared to PG II-infected cells
(data not shown).
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4.2 Subaim 2: To Compare the Pulmonary Pathogenic Phenotypes of HAdVE4 PG I and PG II Genomic Variants in a Cotton Rat Model of HAdV
Respiratory Infection

4.2.1 Description of the Animal Study Design
The cotton rat (Sigmodon hispidus) has been used to study pulmonary
pathogenesis in association with adenovirus infection (110) as well as the
contribution of E1 and E3-encoded proteins in pulmonary pathogenesis (62,
112). These studies exclusively used HAdV-C2 or HAdV-C5. A few other studies
have examined viral pathogenesis of HAdV-E4 (207, 208), but none have
examined the contribution of HAdV-E4 intratypic genetic variability to pulmonary
pathogenesis.
Before using the cotton rat model, the ability of a cotton rat lung epithelial
cell line (CRLC, ATCC PTA-3930) to support viral replication was examined.
CRLC monolayers were infected at a MOI of 5.0 PFU/cell and total infectious
virus yield was determined by plaque assays in A549 cells at various time points
post infection. Replication for both the CL68578 PG I and NHRC 42606 PG II
strains was observed (Figure 24). The yield of infectious virus was between 0.5
and 1.0 logs higher for the PG I strain at 12 and 24 hpi, recapitulating our
observations in A549 cells (Figure 20).
In the in vivo study, 4-week-old female cotton rats (n=6 per group per day)
were infected with 1.0x107 PFU intranasally with either the CL68578 (PG I) strain
or NHRC 42606 (PG II) strain. Animals were sacrificed at 1, 2, 3, and 6 dpi.
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Lungs were harvested and processed for: 1. viral load by qPCR (left lobe), 2.
histopathology (right lung), and 3. cytokine gene expression (left lingular).
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Figure 24: Cotton rat lung cells support HAdV-E4 virus replication in vitro
Submerged CRLC monolayers were infected with PG I or PG II strains at a MOI
of 5.0 PFU/cell in biological triplicate. Infectious virus yield was determined for
the indicated time points by plaque assay in A549 cells.

4.2.2 Fatal Outcomes
Two cotton rats infected with the PG II strain succumbed to infection at 3
dpi. These animals were not available from tissue collection, and no postmortem
examination was performed per standard operating procedure (SOP) at SBI.
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4.2.3 Higher Viral Loads were Detected in the Lungs of Cotton Rats Infected
with the PG I Strain
Viral load in the supernatants of lung homogenates was determined by
qPCR analysis using a proprietary platform developed by DiaSorin Molecular
LLC. Similar numbers of genome copies in the lungs of animals infected with
either strain were observed at one day post infection (Figure 25). For the
CL68578-infected animals, an increase in viral load was observed at 2 dpi with a
gradual decline thereafter, indicating limited viral replication followed by
clearance (Figure 25). In contrast, a continual decrease in viral genome copies in
the lungs of animals infected with the PG II strain was observed at 2-6 dpi,
suggesting rapid clearance following infection (Figure 25).
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Figure 25: Cotton rats infected with the PG I strain had higher pulmonary
viral loads at 2, 3, and 6 days post infection
The viral load was determined using a proprietary qPCR platform developed by
DiaSorin Molecular from the supernatants of left lung homogenates from PG I
and PG II-infected cotton rats at the indicated times post infection. Genome copy
numbers were normalized to the mass of homogenized tissue. n = 6 for each
group.

77

4.2.4 Cotton Rats Infected with the PG II strain Exhibited Enhanced
Pulmonary Pathology than Animals Infected with the PG I Strain
To evaluate the extent of pulmonary pathology resulting from infection in
cotton rats, the right lungs of mock-infected and HAdV-E4-infected cotton rats
were fixed, sectioned, and stained with H&E. The following histological features
were blindly scored by our collaborator Dr. Jorge Blanco at SBI: peribronchiolitis,
perivasculitis, alveolitis, and interstitial pneumonia. Representative H&E-stained
lung sections from animals sacrificed at 1 and 3 dpi are shown in Figure 26A-F.
Animals infected with the NHRC 42606 strain exhibited significantly higher
average combined pathology scores at 1, 2, and 3 dpi (Figure 26G). Specifically,
NHRC 42606-infected cotton rats had higher average alveolitis and interstitial
pneumonia scores, as well as a nonstatistically significant trend of higher
perivasculitis scores (Figure 26G). In addition, the PG II strain-infected animals
had higher average peribronchiolitis scores at 6 dpi. (Figure 26G). Qualitative
examination of the sections at higher magnification revealed the majority of the
infiltrating cells were polymorphonuclear cells and macrophages (data not
shown), which is consistent with descriptions of pulmonary pathology of cotton
rats infected with HAdV-C5 by Prince and colleagues (110).
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Figure 26: Cotton rats infected with the PG II strain exhibited higher
pulmonary pathology scores
(A-F) The right lungs of mock or HAdV-E4-infected cotton rats were harvested
and stained with hematoxylin and eosin for microscopic comparison of lung
pathology: A, mock 1 dpi; B, mock 3 dpi; C, CL68578 1 dpi; D, NHRC 42606 1
dpi; E, CL68578 3 dpi; F, NHRC 42606 3 dpi. Scale = 100 μm. (G) Average
pathology scores of hematoxylin and eosin-stained lung sections. n = 5-6, *p <
0.05, **p < 0.01, Mann-Whittney U test between CL68578 and NHRC 42606.
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4.2.5 Higher Levels of Proinflammatory Cytokine Gene Expression Were
Observed in Cotton Rats Infected With the PG II Strain at One Day Post
Infection
The levels of proinflammatory cytokine gene expression in the lungs of
infected animals were evaluated as reported for other models of respiratory
viral infection (180, 181). At one day post infection, higher levels of
proinflammatory chemokine gene expression was observed in the lungs of
animals infected with the PG II virus including MCP-1, IP-10, and Rantes.
(Figure 27). In addition, statistically higher levels of IL-6 and IFNβ transcripts
were observed in animals infected with the NHRC 42606 strain (Figure 27).
There was a nonsignificant difference in the transcript levels for TNFα and
GRO. These results are consistent with the observation of increased cellular
infiltrates in NHRC 42606-infected animals and the known function of GRO,
MCP-1, IP-10, and Rantes as chemokines (209). Cytokine transcript levels
were evaluated at all other time points, but levels were not found to be
statistically different between groups.
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Figure 27: Higher levels of proinflammatory cytokine gene expression were
observed in cotton rats infected with the PG II strain at one day post
infection
The levels of proinflammatory cytokine gene expression from the lungs of HAdVE4- or mock-infected cotton rats were determined by RT-qPCR.
n = 5-6, p < 0.05 Student’s t test. n=6 for each group.

4.2.6 Summary of Results for Subaim 2
HAdV-E4 strains representative of PG I and PG II exhibited different
replication kinetics and associated pulmonary pathology in a cotton rat model of
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HAdV respiratory infection. Viral load in the lungs of cotton rats infected with the
PG I strain CL68578 increased at 2 dpi and declined thereafter. In contrast,
pulmonary viral load in animals infected with the PG II strain NHRC 42606
decreased steadily through day 6, suggesting rapid clearance. Interestingly,
animals infected with the NHRC 42606 strain exhibited more severe pulmonary
pathology and higher levels of proinflammatory cytokine gene expression
compared with animals infected with the CL68578 strain. Additionally, fatalities
were only documented in animals infected with the PG II strain.

4.2.7 Limitations of this Study
This cotton rat model of HAdV-E4 respiratory infection provides novel
insights into the contribution of HAdV-E4 genetic variability on viral pathogenesis,
however, additional experiments are needed. First, it will be important to evaluate
differences in replication and pathology in both male and female animals. Next,
while this study exclusively examined pulmonary pathogenesis, there are other
organs and portions of the respiratory tract that should also be examined for
pathogenesis and infection such as the liver, lymph nodes, nasal cavity, and
trachea. Also, the cause of death of animals infected with the PG II strain is not
known. From the data of the animals that were sacrificed, it is assumed that they
succumbed to infection, possibly from pulmonary complications resulting from
inflammation. Postmortem examination of these animals would have been
informative. Furthermore, monitoring the animals for signs of illness, such as
weight loss, would also have been informative. Lastly, the cellular source of
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proinflammatory cytokine gene expression during infection is not known. In mice,
alveolar macrophages, not epithelial cells, were found to secrete cytokines (210).
Studies using in situ hybridization of sectioned lung tissue could provide insight
into which cell type(s) produce cytokines at early time points post infection.
Future work will also include immunohistochemical staining for HAdV structural
proteins to identify which pulmonary cell types are infected.
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Chapter 5 – Summary of Findings and Discussion

5.1 HAdV-E4 Strains Isolated Between 1953 and 2015 Comprise Two
Distinct PGs That Have Been Evolving Independently for ~602 Years
In this study the HAdV-E4 intratypic genetic variability was examined by
bioinformatics analysis of WGS of a collection of strains isolated worldwide
between 1953 and 2015. This analysis confirmed the previous observation by Li
and Wadell in 1988 that HAdV-E4 strains cluster into two distinct evolutionary
linages (149). This observation was based on RFLP analysis and assessment of
the PCRF. While PCRF analysis is a low resolution technique (21), it was, at the
time, the only available tool to compare HAdV-E4 genomes. Dehghan and
colleagues also reported distinct phylogenetic clustering of HAdV-E4 strains
(115). The lack of available WGS for a larger sample of HAdV-E4 strains was a
major limitation of their study which included only four strains.
In the present study, WGS of 45 unique HAdV-E4 strains were compared,
making this analysis of HAdV-E4 genetic variability the most extensive conducted
to date. Data from this study also demonstrate the existence of two distinct
clades of HAdV-E4 strains. Both phylogroups (PGs) have very similar intra-PG
sequence identity.
The origins of HAdV-E4 are still debated between researchers in the AdV
research community. It has been suggested that because both PG I and PG II
strains have a genome chassis composed 97% of a SAdV26-like genome with a
hexon containing loops 1 and 2 from HAdV-B16, they originated from an
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interspecies recombination event (115). What has not been elucidated yet is the
estimated timeline of circulation of PG I and PG II strains in human populations
and divergence from a common ancestor. The conclusion that PG II strains
originated from a PG I strain (due to the isolation of PG I strains predating those
of PG II) may be premature (155, 185), as close inspection of PG I and SAdV
WGS separately from PG II and SAdV sequences reveals distinct differences. As
an example, the E1A amino acid sequence identity for PG I strains is closer to
SAdV26 than PG II strains due to the 11 amino acid deletion observed in PG II
sequences. Conversely, sequence identity of the E1B 19K protein is closer for
PG II and SAdV strains as a result of the 11 amino acid deletion in the PG I
strains. Other evidence, including the differences in the vestigial E3 CR1γ region,
suggest at the very least that PG I and PG II strains have been evolving
independently for some time. In agreement with this, Bayesian analysis of the
tMRCA estimates that these PGs diverged 602 ybp and have been evolving
independently since then. The isolation of BC 129, the oldest recorded PG II
strain, dates 13 years before the oldest PG II strain in our collection (V0014, see
Table 4). This suggests that PG I and PG II strains may have been circulating for
similar periods of time, and the estimated tMRCA would be more accurate if the
whole genomic sequence for BC 129 was available. Additionally, describing PG I
and PG II strains as “old” and “new” strains, respectively (155), or as “emerging”
(199) is misleading because they likely have been cocirculating in human
populations for a long period of time but went undetected until the 1950s and
1960s. Furthermore, it is likely there are many unreported infections and
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outbreaks due to a lack of robust surveillance programs monitoring HAdV
outbreaks and the generally self-limiting nature of HAdV-E4 infections.
I hypothesize that the higher mutation rate observed in PG II strains is due
to a higher number of infections by PG II that increased the overall frequency of
mutations despite a similar mutation rate in each replication cycle. The
documented higher frequency of isolation of PG II strains from cases of HAdVE4-associated disease suggests that these viruses may have a higher level of
viral fitness or may be more virulent.

5.2 Strains of PG I and PG II Differ in Their in vitro and in vivo Phenotypes
Relevant that are to Pathogenesis
Analysis of 45 HAdV-E4 WGS showed that PG I and PG II strains share
approximately 94.5% sequence identity. This study identified differences in
coding and noncoding regions among PG I and PG II genomes. The discussion
of the implications of these genetic differences for the observed in vitro and in
vivo phenotypes is detailed below.
PG I strains, particularly the CL68578 vaccine strain, form larger plaques,
have enhanced virus spread and cell killing phenotypes, and have faster
replication kinetics compared to PG II strains. Interestingly, variability in these
phenotypes was observed among PG I strains. The CL68578 strain formed the
largest plaques and had the fastest plaque development rate compared to any
other strain tested. Intermediate phenotypes were also observed for other PG I
strains in cell viability assays. The PG I strains CL68578 and RI-67 strains were

89

isolated within a period of nine years (see Table 4) and are 99.95% identical. The
genomes have only 20 nucleotide differences, 12 of which map to the ITRs
(although the ITR regions for CL68578 and the RI-67 ATCC VR-1572 stock are
identical). The other differences are located in E2B, late region 1 (L1), L3, and
L4. The only nonsynonymous mutations distinguishing both strains map to the
L4-100K CDS (T357I) and an in frame three nucleotide insertion (alanine) in the
vaccine strain in the L4-33K CDS. This alanine insertion is also present in all the
PG II strains. At present, it is unclear which of these differences contributes to
the plaque phenotype. It is also unclear if these in vitro differences will translate
to differences in pathogenicity in the cotton rat model. As reported by Kajon and
colleagues, only 10 point mutations distinguish the PG I strain NY-15-4054 from
the CL68578 vaccine strain (128). Slightly different cell killing and plaque size
phenotypes were observed between these two strains. The NHRC 90339 strain,
a 4p4 variant (139), is 99.66% identical to the vaccine strain, showing the highest
level of divergence of any of the PG I strains. Additionally, this strain also had the
smallest plaques of any PG I strain. The growth phenotype among all PG I
strains, however, was similar.
Interestingly, no phenotypic differences were observed between the PG II
strains in plaque size, cell killing, virus spread, or replication kinetics (Figures 1518 and 21). PG II strains have an average intra-group sequence identity of
99.88% compared to the earliest isolated PG II strain in our collection, strain 13.
The only noticeable difference among the PG II genomes was a 194 bp insertion
adjacent to the right hand ITR in strain 29. This strain was not included in the
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panel of viruses for the in vitro or in vivo studies, so the implications of this
insertion for replication remains to be evaluated. It is interesting that while in vitro
phenotypic variability in PG I strains with an overall similar inter-PG I percent
sequence identity was observed, no phenotypic differences were observed
among PG II strains. It is possible that our assays were not sensitive enough to
detect subtle phenotypic differences between PG II strains.
The genetic determinants of the large plaque phenotype observed among
PG I strains are unknown. Large plaque phenotypes can be a result of several
factors, including virus replication and enhanced cell killing (69). The results from
the studies described in this dissertation suggest that the large plaque phenotype
of PG I strains may be a result of both mechanisms. Growth curve experiments
show a lag in virus replication among PG II strains at 24 hpi, although infectious
titers were comparable at 48 and 72 hpi. Additionally, more infectious virus was
detected in the apical compartment of infected Calu-3 cells. Enhanced replication
kinetics can be attributed to the genetic makeup at several regions of the HAdV
genome, including the ITRs and E1A.
Mutations in the ITR sequences have been shown to affect viral
replication. Wunderlich and colleagues reported that a change in the terminal 8
bp of the ITR sequences (5’-CATCATCA-3’ to 5’-CTATCTAT-3’) can dramatically
improve viral replication efficiency of E1-depleted HAdV-B35 vector using E1
complementing cell lines (211). Additionally, they report that the majority of
human and nonhuman AdVs carry the “original” 5’-CATCATCA-3’ terminal
sequence with some reported sequences carrying “alternate” ITRs (211). The
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present study reports differences in HAdV-E4 ITR sequences. Specifically, the
RI-67 strain contains a variant 5’-CTATCTAT-3’ sequence while CL68578 and
most others carry the 5’-CATCATCA-3’. In addition, a minority of HAdV-E4
strains examined in this study have various other sequences (Figure 10).
Wunderlich and colleagues demonstrated that their recombinant HAdV-B35
vector with the 5’-CTATCTAT-3’ terminus replicated faster than a vector
encoding the terminal 5’-CATCATCA-3’ sequence (211). In the present studies,
the RI-67 strain replicates similarly in culture to CL68578, although the vaccine
strain exhibits larger plaque sizes. The strains with other alternate terminal
sequences were not used in in vitro studies, so it remains to be seen if these
noncanonical sequences contribute to differences in the replication phenotype. It
is important to note that some of these variant sequences carry trinucleotide
terminal direct repeats (for example 5’-AATAATAT-3’ or 5’-ATAATATA-3’) which
are important in the “jumping-back” mechanism of replication proposed by King
and van der Vliet (212, 213). Some alternative sequences do not have a terminal
direct repeat, which may indicate limitations in the sequencing technology used.
Wunderlich and colleagues could not recapitulate this phenotype when
manipulating the ITR sequence of a recombinant HAdV-C5 vector, which may
indicate that the enhanced growth kinetics phenotype documented for the 5’CTATCTAT-3’ sequence may be limited to HAdV-B35.
Dehghan and colleagues identified differences in the nuclear factor
recognition sites among a small sample size of PG I and PG II genomes. They
found that the NFI recognition site in PG II ITRs is remarkably similar to those in
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HAdV-B genomes and suggested that this “adapted” NFI binding site may
enhance replication (115). This hypothesis was again stated in another study
describing recent HAdV-E4 viruses circulating in China (199). Conserved NFI
and NFIII transcription factor binding sites in HAdV ITRs have been shown to
enhance replication in vitro. However, these binding sites in PG I ITRs are not
required for replication and only the terminal 18bp of the ITR is necessary for
initiation of replication (77, 78). Instead, an unidentified nuclear factor from a
HeLa cell extract enhanced in vitro replication, suggesting a different mechanism
(77). It is possible that the PG II ITR, with an “adapted” NFI site, might enhance
initiation and subsequent replication better than the PG I ITR, however, there are
no reports that have compared PG I and PG II ITR initiation in vitro. The work
presented in this dissertation suggests that PG I strains replicate more efficiently
in vitro and in vivo, although this phenotype cannot specifically be attributed to
the ITR, as numerous sequence differences throughout PG I and PG II genomes
were identified, many of which were in regions that have been shown to affect
viral replication.
Using HAdV-C as a model, it has been demonstrated that mutations in
conserved regions in E1A leads to inefficient stimulation of other early viral genes
and stunts replication at low MOIs (214). The bioinformatics analysis of the E1A
gene conducted in this study identified an 11 amino acid deletion in all PG II
genomes between CR1 and CR2. This region is highly variable among the
species of HAdV and no specific function has been attributed to the residues in
this region. There are several residues, however, that are conserved among the
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different species in this region, including a leucine at position 91 and a threonine
at position 93, that have not been associated with any particular function. Several
publications have shown that variation in E1A between HAdV-E4 and other
HAdV species results in differential interaction with cellular factors (189, 215,
216). These studies only used PG I E1A proteins, and follow up studies with E1A
from PG II strains would be necessary to elucidate if there are differences
between species in E1A binding to cellular proteins.
Enhanced cell killing can also result in a large plaque phenotype. Two
important genes that influence plaque size as a result of cell killing are the HAdVC-specific ADP proteins and E1B 19K. ADP has been shown to promote viral
progeny release in WT viruses (69, 87) and its overexpression greatly enhances
this characteristic (202, 203). The mechanism of action of ADP remains to be
elucidated. HAdV-E4 strains do not encode the ADP gene, and mutant PG I
strains (derived from the CL68578 strain) which do not encode the HAdV-E4specific E3 CR1 proteins (located in the same region as ADP in HAdV-C) do not
exhibit a reduction in plaque size or slower replication kinetics (data not shown).
Using random UV mutagenesis of the ADP-null mutant (strain dl327),
Subramanian and colleagues isolated large plaque mutants. They determined
that 62% of these viruses had mutations in the E1B 19K gene. Dysregulation of
the apoptosis pathway led to increased cell lysis (89). Radke and colleagues also
discovered decreased E1B 19K expression in a HAdV-B14p1 strain compared to
the HAdV-B14p strain also led to larger plaque size, although the specific
mechanism was not elucidated (90). While sequence divergence among AdV
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types has been noted for the E1B polypeptides (187, 217, 218), the effect of
variation in E1B promoter activity (219) and the functional differences of E1B 19K
and E1B 55K proteins among the different HAdV species have only been
examined to a limited extent (187, 220–222). For HAdV-E4, differences in the
E1B coding regions map to regions that are not well conserved among the HAdV
species (217), and future work will be needed to elucidate the contribution of
mutations, if any, to the function of the E1B-encoded proteins during infection.
Higher levels of pulmonary pathology were observed in cotton rats
infected with the PG II strain NHRC 42606 compared to the PG I vaccine strain.
There are several explanations for this result. One hypothesis is that animals
infected with the PG II strain may not express high levels of HAdV-E4-encoded
immunomodulatory proteins as a result of decreased viral replication. In the
cotton rat studies, an increase in viral load at 2 dpi in animals infected with the
PG I strain was observed, followed by a steady decline thereafter. In contrast,
there was no increase at any time point in viral load in lungs of animals infected
with the PG II strain. Immunomodulatory functions are encoded in several
regions of the genome, including E1, E3, E4, and VA RNA (55). It has been
shown that prevention of AdV genome replication suppressed E3 gene
expression (223). Therefore, increased viral replication would result in increased
levels of the early and late gene products, and thereby have a greater effect in
modulating the host response to infection.
Another explanation may be that the genetic variability in the genes that
modulate the host response to infection affects pathogenicity. The specific impact
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of the genetic variability in E1, E3, L4, and VA RNA on their function is not
known. The CR1 region of the E1A as well as E1B 55K are known to potently
block expression of interferon-stimulated genes (ISGs) (224–226). These
functions have never been tested for HAdV-E4 strains, and further work will be
needed to characterize differences, if any, between PG I and PG II strains in
modulation of ISG expression. E4 ORF3 acts to block promyelocytic leukemia
protein (PML) body formation and antagonizes the IFN response (58, 227, 228).
In the present study, however, no significant difference in this coding region was
observed.
The noncoding VA RNAs antagonize PKR activation and saturate the
DICER complex (55, 229). While mutation of the HAdV-C5 VA RNAs results in a
60 fold decrease in viral titers, only a 20 fold decrease was seen when VA RNAI
alone was deleted, and no measurable difference was observed when only VA
RNAII was deleted (72, 190). This appears to be the result of limited levels of Pol
III during the late phase of infection with the consequence of preferential
transcription of VA RNAI (190). Studies examining the effects of HAdV-E4 VA
RNAs have not been reported and would be important for the elucidation of the
role of each VA RNA in replication. This work also identified differences in VA
RNAII for 4p4 PG I genomic variants, including partial deletion of one of the
protomer elements. Further experiments are needed to elucidate the impact of
this mutation on transcription of VA RNAII. It is possible that reduced IFN
antagonism by VA RNAs of PG II strains could elicit a stronger immune response
and will need to be evaluated in an animal model.
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The major neutralizing epitopes for HAdVs are located in the major
structural proteins: hexon, penton base, and fiber (230–233). Hexon evolution is
driven by illegitimate recombination and mutations caused by polymerase
slippage in the HVR 1-7 regions (192). This work identified several synonymous
and nonsynonymous mutations in HVR 1 and 3-7 that distinguish PG I and PG II
strains. The impact of this genetic drift observed among HAdV-E4 strains is
unknown, and likely doesn’t impact the observed in vitro and in vivo phenotypes.
Recently, Tian and colleagues published the identification of a neutralizing
epitope for the HAdV-E4 hexon in HVR 7 (234). This epitope was conserved
among all 45 HAdV-E4 strains examined in the present study (data not shown).
In VN assays, PG II strains are neutralized with antisera raised against the PG I
strain RI-67 (123, 125, 126), although Crawford-Miksza and colleagues reported
a fourfold reduction in neutralization in a PG II strain (169). The present work
identifying additional differences in the hexon HVR regions provides the rationale
for additional VN tests encompassing a more comprehensive panel of HAdV-E4
strains.
The multifunctional L4-100K protein aids in hexon trimerization (84),
efficient translation of late mRNAs (235, 236), and prevents granzyme Bmediated cell death (237). Each of these functions is important in virus
replication. PG I and PG II genomes exhibit differences in the GAR region of the
L4-100K protein, which may affect the methylation state of the protein. Disruption
of these methylation sites negatively impacts viral replication for HAdV-C5 (196,
238). The methylation state for HAdV-E4 strains has not been determined and
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future work is needed to identify if genomic differences in the L4-100K coding
region affects virus replication.
The proteins encoded in E3 also modulate the host response to infection
in a variety of ways as previously discussed. The most dramatic differences in E3
for HAdV-E4 map to the species-specific E3 CR1 genes, E3 CR1β and E3 CR1δ.
Martinez-Martin and colleagues demonstrated physical interaction between the
ectodomain of E3 CR1β and the host LILRB1 protein, which could have
implications on the activation of NK cells (71). The implication of intratypic
genetic differences in E3 CR1β are currently not known. While the function of E3
CR1δ has not been reported, preliminary work in our laboratory using a E3 CR1δ
KO mutant in a genomic clone of the CL68578 strain has showed that it may be
involved in modulating the inflammatory response in our cotton rat model (data
not shown). Further work is needed to characterize the differences, if any, in
pulmonary inflammation between the PG I and PG II-encoded E3 CR1δ.
Previously, marked increase in peribronchiolitis, perivasculitis, and alveolitis
scores were observed in cotton rats infected with a HAdV-C E3 gp/19K mutant
compared to the WT control (62). PG I and PG II strains show conservation in the
gp/19K polypeptide, including conserved cysteines thought to be important for
the function of the HAdV-C5-encoded protein (239). Further biochemical
characterization will be needed to determine if there is a difference among HAdVE4 strains in the ability to sequester MHC I molecules in the ER.
Few studies have correlated HAdV intratypic genetic differences to in vitro
or in vivo phenotypes. Using the Syrian hamster model, Radke and colleagues
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found that a HAdV-B14p1 strain, which produced larger plaques in vitro, elicited
a markedly higher inflammatory response in the lungs compared to the HAdVB14p strain. The authors attributed this result to reduced E1B 19K expression by
the HAdV-B14p1 strain. They showed that fixed HAdV-B14p1-infected A549 cells
stimulate a strong NF-κB-dependent cytokine response from macrophages in
culture and observed higher amounts of infiltrating immune cells in the alveolar,
peribronchiolar, and perivascular spaces in their animal model (90). The work
presented in this dissertation using the cotton rat model of HAdV-E4 respiratory
infection produced the opposite result: the PG II strain (small plaques) elicited a
stronger inflammatory response in the lungs than the PG I strain (large plaques).
Additionally, higher levels of cytokine gene expression in the lungs of animals
infected with the PG II virus was observed. It is likely that the mechanisms
underlying the phenotypes observed in our studies and those reported by Radke
and colleagues for HAdV-B are different.
Another example of correlating in vitro and in vivo phenotypes is HAdV-C
ADP laboratory mutants. There is ample evidence in the literature demonstrating
differences in plaque size and cell killing phenotypes among WT and ADPmutants (69, 87). Ginsberg and colleagues did not observe a difference in
pneumonia of cotton rats infected with an ADP mutant (62). This suggests that
increased cell lysis due to the activity of ADP did not trigger a stronger
inflammatory response compared to the ADP-null mutant, although cellular lysis
due to ADP was not specifically addressed by Ginsberg and colleagues using
this model (62). In agreement with this, Tollefson and colleagues hypothesized
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that an apoptosis-like mechanism is responsible for ADP-dependent cell death in
HAdV-infected cells (69). HAdV-E4 strains do not seem to encode an ADP-like
CR1 protein. Furthermore, the mechanism of cell death is currently not known for
HAdV-E4 strains, and further work will be needed to determine if cell death from
PG II virus-infected cells is proinflammatory compared to PG I virus-infected
cells.

5.3 Future Directions
This work builds the foundation for future investigation into the molecular
basis of HAdV-E4 pathogenesis. This work has identified distinct phenotypic
differences between PG I and PG II strains in cell culture regarding plaque size
and development, growth kinetics, viral progeny release, and cell killing as well
as differences in pathogenesis in a cotton rat model of HAdV respiratory
infection. The gene product(s) that contribute to these in vitro and in vivo
phenotypes are unknown. The most straightforward way to address this question
is assessment of these phenotypes using isogenic mutant viruses.
I propose the use of the PG I CL68578 genome clone, pVQ WT #11183
which our laboratory has obtained under material transfer agreement with
Advanced Bioscience Laboratories Inc.. The protocols for constructing mutant
viruses in our laboratory have already been established and a cartoon schematic
of this process is shown in Figure 28. Briefly, a shuttle plasmid containing the
target region of interest (ROI) from a HAdV-E4 genomic variant is obtained either
by conventional cloning techniques using purified PG II DNA, or it is
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commercially synthesized. Recombination of the ROI from the shuttle into the PG
I genomic clone is then performed using commercially available homologous
recombination-competent E. coli cells. This new mutant genomic clone is then
linearized to remove the pBR322 low copy plasmid sequence and transfected
into A549 cells. Infectious supernatants from freeze-thawed cell culture material
are then serially passaged in A549 cells until high titers of virus are obtained.
I propose the construction of several mutant PG I viruses that encode PG II
ROIs to elucidate the molecular basis of HAdV-E4 pathogenesis. The candidate
ROIs include genes in the following regions: E1A, E1B, L4, and E3. In addition, I
propose the construction of mutant PG I viruses that carry the PG II sequences
for the ITR and VA RNAII. E1A is a potent transactivator of viral early gene
transcription (41, 42). Growth experiments showed higher levels of PG I
infectious virus at early time points, which may indicate deficiencies in early gene
expression in PG II viruses. Mutations in the ITR regions also affect virus
replication kinetics (211, 240), and substitution of the PG II ITR into the PG I
backbone may be sufficient for decreased replication kinetics in vitro. E1B 19K
and E1B 55K are potent inhibitors of apoptosis, and decreased E1B 19K gene
expression has been shown to increase apoptosis (90, 241). Viruses with
mutations in E1B 19K have been shown to exhibit larger plaque sizes (89, 90).
PG I viruses have larger plaque sizes, which may suggest decreased E1B 19K
expression. L4-100K is an important regulator of late gene expression (235), and
disruption of arginine methylation negatively affects replication (196). Differences
in the L4-100K coding region affecting post-translational methylation could
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explain faster replication kinetics among PG I. E1A, E1B, E3, and VA RNA
modulate the host response to infection (59, 224, 225, 242, 243), and differences
in these regions may contribute to the increased pulmonary inflammation
observed in cotton rats infected with the PG II strain.
It is possible that differences in multiple coding regions contribute to the in
vitro and in vivo phenotypes observed in these studies. Differences in
phenotypes from isogenic laboratory mutant viruses are attributed to the gene or
region that is manipulated. The viruses tested in this study are naturally occurring
variants with multiple differences across the entire genome, and multiple loci may
be contributing to the observed phenotypes. For example, differences in E1A,
E1B, E3, and VA RNA are present among PG I and PG II strains, and the
reduction in the pulmonary inflammatory response observed among PG I strains
may be a result of a synergistic contribution of one or more of these coding
regions. Another example is the mechanisms that underly the large plaque
phenotype observed in AdVs. It is possible that PG I strains induce apoptosis to
a greater extent than PG II strains via differences in E1A and simultaneously
have limited expression of E1B which prevents apoptosis. Therefore, the
reduction of plaque size may only be readily observed when mutating both the
E1A and E1B regions. As previously mentioned, multiple coding and noncoding
regions of the genome affect virus replication, and manipulation of multiple loci in
the PG II genome may be needed to observe the PG II phenotype.
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Figure 28: Mutant HAdV-E4 construction strategy
The PG I CL68578 genome is available in a genomic clone (pVQ WT#11183).
A shuttle plasmid is constructed either using conventional cloning from purified
PG II virus DNA or commercially synthesized and contains the PG II sequence
for a region of interest (ROI). Homologous recombination is then performed
using commercially available homologous recombination-competent E. coli cells
to recombine the PG II ROI into the PG I backbone. The new mutant genomic
clone is then linearized using the PacI restriction endonuclease to remove the
bacterial plasmid sequence and transfected into A549 cells. After several
passages in A549 cells, high titers of virus are produced.
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5.4 Perspectives
This work provides novel insights into the magnitude and spectrum of
HAdV-E4 intratypic genetic variability and reveals differences in phenotypes that
are relevant to pathogenesis. HAdV-E4 genome variants, distinguishable by
RFLP analysis or by comparison of WGS, cluster into two distinct evolutionary
lineages which share approximately 95% sequence identity. Novel observations
in sequence differences between PG I and PG II strains in the ITR, E1, L3, L4,
and E3 regions distinguish these PGs. These phylogenetic groups are further
distinguished by their in vitro growth, cell killing, and spread phenotypes and
importantly by their in vivo pathogenic phenotypes. These variants are all
neutralized with animal antiserum raised against the HAdV-E4 prototype strain,
and thus have never been distinguishable as separate serotypes. The work in
this dissertation clearly demonstrates that while they are serologically similar,
their biological characteristics are different. Currently, biological characteristics
(except for VN and HI) are not sufficient criteria for separating PG I and PG II
strains into two separate genotypes as the genetic makeup at loci encoding the
major capsid proteins (penton base, hexon, and fiber) has not been considered
different enough to justify a distinction. Therefore, the use of the phylogroup
designation to distinguish HAdV-E4 strains for epidemiology or pathogenesis
studies would be helpful. PG I is defined as strains having a sequence identity of
99-100% to the RI-67 strain, large plaque sizes, faster replication kinetics, and
low pathogenicity in the cotton rat model. PG II is defined as having 93-96%
sequence identity to RI-67, small plaque sizes, slower replication kinetics, and
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high pathogenicity in the cotton rat model. These new designations are more
meaningful as they reflect the distinct genomic characteristics in addition to
differences in in vitro and in vivo phenotypes. In the future, when molecular data
are available (such as typing by RFLP, PCR, or NGS), reports should include the
strain and phylogroup designation. Furthermore, as the diagnostic field has
shifted to adopt molecular tools for typing clinical isolates, there are opportunities
to develop assays that can distinguish PG I and PG II strains.
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Appendices
Appendix A – Abbreviations
%G+C – Percentage of genomic guanine-cytosine content
ADP – Adenovirus death protein
AdV – Adenovirus
AICc – Akaike information criterion
ARD – Acute respiratory disease
CAR – Coxsackie and adenovirus receptor
CBP – p300/CREB-binding protein
CO2 – Carbon dioxide
CPE – Cytopathic effect
CR – Conserved region.
CRLC – Cotton rat lung cell
DBP – DNA binding protein
dpi – Days post infection
E1 – Early region 1
E2 – Early region 2
E3 – Early region 3
E4 – Early region 4
ER – Endoplasmic reticulum
GI – gastrointestinal
H&E – Hematoxylin and eosin
HA – hemagglutinin
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HAdV – Human adenovirus
HAdV-E – Species Human mastadenovirus E
HAdV-E4 – Human adenovirus type 4
HI – Hemagglutination inhibition
HI-NBCS – Heat-inactivated newborn calf serum
hpi – Hours post infection
HSCT – Human stem cell transplants
ICTV – International Committee on Taxonomy of Viruses
IFN – Interferon
INDEL – Insertion and deletion
ISG – Interferon-stimulated gene
ITR – Inverted terminal repeat
KO – Knock out
L1 – Late region 1
L2 – Late region 2
L3 – Late region 3
L4 – Late region 4
L5 – Late region 5
LDH – Lactate dehydrogenase
MEM – Minimum Essential Medium
MLP – Major late promoter
MOI – Multiplicity of infection
NBCS – Newborn calf serum
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NGS – Next generation sequencing
NHP – Nonhuman primate
ORF – Open reading frame
PBS – Phosphate buffered saline
PBS++ – Phosphate buffered saline with magnesium and calcium
PCR – Polymerase chain reaction
PCRF – Percentage of comigrating restriction fragments
PFU – Plaque forming unit
PG – Phylogroup
PG I – Phylogroup I
PG II – Phylogroup II
PKR – Protein kinase R
PML – Promyelocytic leukemia protein
pol – Adenovirus DNA-dependent DNA polymerase
Pol III – RNA polymerase III
pTP – preterminal protein
RB – Retinoblastoma protein
RFLP – Restriction fragment length polymorphism
ROI – Region of interest
RT – Room temperature
RT-qPCR – Real-time quantitative PCR
SBI – Sigmovir Biosystems Inc.
SEM – Standard error of the mean
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SOP – Standard operating procedure
TER – Transepithelial electrical resistance
tMRCA – Time to the most recent common ancestor
TP – Terminal protein
TPL – Tripartite leader
VA RNA – Virus-associated RNA
VA RNAI – Virus-associated RNA I
VA RNAII – Virus-associated RNA II
VN – Virus neutralization
WGS – Whole genome sequences
ybp – Year before the present
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